ERK5 is required for melanoma growth and is activated by oncogenic BRAF by Gagliardi, Sinforosa

Dottorato di Ricerca in Scienze Biomediche (Ciclo XXX) 
Curriculum: ONCOLOGIA SPERIMENTALE E CLINICA 
Candidato: SINFOROSA GAGLIARDI 
ABSTRACT 
ERK5 is required for melanoma growth and is activated by oncogenic BRAF 
 
Malignant melanoma is among the most aggressive cancers and its incidence is increasing 
worldwide. Although targeted therapies and immunotherapy have improved the survival of 
patients with metastatic melanoma in the last few years, available treatments are still 
unsatisfactory showing an urgent need to identify new therapeutic targets. While the role of 
BRAF-MEK1/2-ERK1/2 pathway in melanoma is well-established, the involvement of the 
MEK5-ERK5 signaling remains poorly explored. The Hedgehog signaling is an important 
pathway in melanoma, that has been shown to be required for growth, recurrence and metastasis 
of melanoma xenografts in mice. Several studies have shown that numerous oncogenic inputs 
positively modulate the activity of the HH pathway.  
In this study, we investigated the function of ERK5 signaling in melanoma, its regulation 
by oncogenic BRAF and its interplay with the HH pathway. We show that ERK5 is consistently 
expressed and active in human melanoma cells. Genetic silencing of ERK5 and pharmacological 
inhibition of the MEK5-ERK5 pathway drastically reduce the growth of melanoma cells 
harboring wild type (wt) or mutated BRAF (V600E), in vitro and in vivo.  
We also found that oncogenic BRAF positively regulates expression, phosphorylation 
and nuclear localization of ERK5. Importantly, BRAF enhances ERK5 kinase and transcriptional 
transactivator activities. Nevertheless, combined pharmacological inhibition of BRAF-V600E 
and MEK5 is required to decrease nuclear ERK5, that is critical for the regulation of cell 
proliferation. Accordingly, combination of MEK5 or ERK5 inhibitors with BRAF-V600E 
inhibitor Vemurafenib is more effective than single treatments in reducing the tumor growth of 
BRAF-V600E melanoma cells and xenografts.  
Moreover, we have also identified the existence of an interplay between the HH pathway 
and ERK5. By chemical and genetic inhibition of ERK5, we demonstrate that ERK5 positively 
modulates the HH pathway, increasing transcriptional activity and protein levels of the GLIs 
transcription factors, the final effectors of HH signaling.  
These data support a key role of ERK5 pathway for melanoma growth in vitro and in vivo 
and suggest that targeting ERK5, alone or in combination with BRAF-MEK1/2 inhibitors or HH 
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1.1  Melanoma 
Skin cutaneous melanoma is a tumor that arises from the malignant transformation of 
melanocytes, the melanin-producing cells present in the deep layer of the epidermis. 
Melanocytes derive from melanoblasts, which originate from the multipotent cells of 
the neural crest. During development, these cells migrate to several districts, mainly 
dermis and hair follicles, where they differentiate into mature melanocytes. In the skin, 
differentiated melanocytes respond to ultraviolet radiation by synthesizing melanin 
pigment, then transferred to keratinocytes. A pool of melanocytes with stemness 
properties (MSCs) remains in the lower permanent portion of skin and the hair follicle, 
where they ensure a continuous regeneration of mature melanocytes through self-
renewal and differentiation (Mort et al., 2015). Maintaining balance between the 
proliferation of melanocytic stem cells and their differentiation is a very critical process, 
to which many genetic and environmental factors contribute. Oncogenic events, as the 
deregulation of genes involved in cell cycle control or in differentiation, might alter this 
balance providing the basis for melanoma initiation (Regad, 2013). Melanocytes are not 
confined to the epidermis. Outside the skin, melanocytes are present in considerable 
number in the uveal tract of the eye and at lower densities in other tissues, such as the 
meninges, the anogenital tract, basal epidermis layer, mucous membranes and vascular 
veins. Consequently, melanoma can interest not only the skin, but all body regions 
where melanocytes are present, giving rise to melanocytic neoplasms different in their 
clinical, histopathological and genetic characteristics from cutaneous melanomas 
(Bastian, 2014). 
 
1.1.1 Melanoma incidence and risk factors 
Although melanoma constitutes only a small percentage (about 6%) of all skin tumors, 
it is one of the most aggressive forms of skin cancer due to its propensity to develop 
metastasis. Indeed, it causes 65% of deaths for skin cancer and represents 5% of all 
male tumors (5th tumor per relative incidence) and 4% in female sex (7th tumor per 
relative incidence). It affects mainly subjects between 30 and 60 years of age and rarely 
interest younger patients. The global incidence of cutaneous melanoma is approximately 
200.000 new cases per year, with 5-year survival rates ranging from 15% to 60% in 
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patients with distant and local metastases, respectively. In recent years, a significant 
increase in the incidence of the disease has been reported, probably due to the different 
habits of exposure to UVA and UVB sun exposure, considered one of the major risk 
factors (Siegel et al., 2017). 
As with different types of cancer, both genetic and environmental factors 
contribute to the development of melanoma. The incidence of melanoma is strongly 
influenced by UV exposure, pigmentation of the skin (phototype I and II more sensitive 
to UV demage), geographic parameters (latitude and altitude), presence of congenital or 
acquired nevi, light immune deficiency and genetic predisposition. Approximately 10% 
of melanomas occur in a familial context and are characterized by rare deleterious 
germinal mutations in the cell cycle regulators CDKN2A, cyclin dependent-kinase 4 
(CDK4) and in the master gene of melanocyte homeostasis microphthalmia-associated 
transcription factor (MITF). Additionally, the frequent allelic germinal variants of other 
genes are associated with low-risk susceptibility (MC1R, ASIP, MTAP and Caspase 8) 
(Dahl et al., 2007; Chin et al., 2003). 
Epidemiologic studies reveal that sun exposure is the major known 
environmental factor associated with development of melanoma. The high mutation rate 
in melanoma is largely attributed in particular to mutagenic effects of UVR, with 
multiple effects in the skin, including genetic changes, formation of reactive oxygen 
species (ROS), alterations in cutaneous immune function, and production of growth 
factors (Garibyan et al., 2010). All these events induce accumulation of genetic 
mutations in melanocyte that activate oncogenes, inactivate tumor suppressor genes and 
impair DNA repair promoting melanocyte proliferation, blood vessel growth, tumour 
invasion, evasion of immune response and, lastly, metastasis (De Braud et al., 2003; 
Thompson et al., 2005). 
 
1.1.2. Clinical classification and stadiation 
Melanoma can be classified into 4 different clinical subtypes: superficial spreading 
melanoma (the most common, represents about 70% of all skin melanomas), lentigo 
malignant melanoma, acral lentiginous melanoma and nodular melanoma (the most 
aggressive, represents approximately 10-15% of skin melanomas). Among these 
subtypes, the first three are characterized by superficial growth and good prognosis. 
Instead, nodular melanoma is more aggressive and invasive since its early stages. There 
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are also rare histopathological variants, such as desmoplastic and nevoid melanoma 
(McCourt et al., 2014). 
According to the American Joint Committee on Cancer (AJCC) melanomas are 
currently classified into four stages, designated from I to IV; whereas stage 0 indicates 
in situ melanoma, which only affects the top layer of the skin. The melanoma staging 
recommendations were made on the basis of a multivariate analysis of 30,946 patients 
with stages I, II, and III melanoma and 7,972 patients with stage IV melanoma. These 
stages were defined on the basis of the TNM system, which is based on 3 key 
informations about the tumor: characteristics of the primary tumor (T), involvement of 
lymph nodes (N) and presence of metastasis (M). The revisions to the AJCC melanoma 
staging system over time (the 7th edition is the current) reflect progresses in the 
understanding of the biology of the disease, essential to improve melanoma prognosis of 
patients (Boland et al., 2016). 
 
 
Figure 1.1 Melanoma staging (Image by MedArs.it., 2001).  
 
In the characterization of the primary tumor, the thickness of the lesion is an 
important parameter to evaluate during the evolution of melanoma, also for the 
prognosis of the disease. Breslow staging provides a measure of the degree of 
penetration of melanoma from the superficial granular layer to the deeper and inner 
level of the skin. The prognosis is good for melanomas less than 1 mm and 





Figure 1.2 Breslow system for tumor thickness evaluation (Image by MedArs.it., 2001). 
 
Other important prognostic indicators are the presence of ulcerations, an 
unfavorable event that allows to predict a greater chance of metastasis at the visceral 
and bone. The mitotic index, which indicates proliferative activity, is also associated 
with unfavorable prognosis. Instead, the degree of lymphocyte infiltration in the tumor 
is a favorable event but is very low in most patients (Regad, 2013). The prognosis of 
melanoma is also conditioned by the localization of the tumor mass and by the tumor 
stage at diagnosis. While early-stage primary melanoma can be successfully treated by 
surgery, metastatic forms are refractory to all available therapies. To improve the 
prognosis of the disease, a periodical evaluation of primary lesions is essential to ensure 
an early diagnosis and an effective therapy. The acronym ABCDE summarize some of 
the features to be evaluated in nevi (McCourt et al., 2014): 
A: Asymmetry 
B: Border irregularity 
C: Colour variation 
D: Diameter > 6 mm 
E: Evolving  
 
The histologic changes that accompany the progression from normal melanocytes 
to malignant melanoma are described in the Clark model. The model depicts the 
stepwise transformation of melanocytes to melanoma as a process of forming nevi and 
the subsequent development of dysplasia, hyperplasia, invasion and metastasis. The 
initial phase is characterized by a radial growth. The melanocytes can proliferate as 
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isolated cells or arranged in small nevi, confined at the epidermis or papillary dermis. 
This phase can last for a few months to years and is characterized by the absence of 
aggressive behavior and good prognosis. Indeed, melanoma cells at this stage are still 
dependent on exogenous growth factors due to stimulation by the keratinocytes and are 
incapable of growing in an anchor-independent manner. The next phase of vertical 
growth represents a more malignant stage of the tumor: the atypical and mitotic 
tendencies are more apparent and frequent; the neoplasia begins to spread perpendicular 
to the epidermis, invading the reticular dermis and forming nodules of proliferating 
malignant cells. At this stage, melanoma cells escape by keratinocytes stimulation and 
establish close interaction with stromal cells. They acquire autonomous proliferation 
capacity and cohesive growth, with aggregate or nodule formation extending to the 
reticular dermis or subcutaneous tissue, acquiring invasive and metastatic properties. 
The transition from the radial to vertical growth phase constitutes the crucial step in the 
progression of melanoma, indicative of the acquisition of a metastatic phenotype with 
worse prognosis (Miller et al., 2006).  
 
	
Figure 1.3 Proliferation of melanocytes at different stages of melanoma progression (Modified from 
Miller et al., 2006). 
 
Several molecular and genetic events have been associated with different stages of 
melanoma development. The study of the resulting biological events is important to 






1.1.3. Signaling pathways altered in melanoma 
Melanoma is a heterogeneous tumor and several molecular events have been identified 
and associated with its development (Alexandrov et al., 2013). In addition to germline 
mutations, the main players of melanomagenesis may acquire successive genetic lesions 
to promote tumors formation. The cascade of genetic events occurring in tumor 
neoplastic progression can be described following a linear progression pattern, based on 




Figure 1.4 Hypothetical model for melanoma progression (Bertolotto, 2013). 
 
The identification of mutations involved in making an individual melanoma cell 
competent for metastatic spread is crucial to understand melanoma progression. In 
recent years, genomic sequencing studies of melanoma have uncovered mutations in 
multiple genes and pathways involved in important cellular processes, such as 
proliferation, apoptosis, senescence and response to DNA damage (Figure 1.5) 
(Krauthammer et al., 2015; Hodis et al., 2012; Mar et al., 2013). The study of driver 
melanoma gene mutations may offer not only the possibility to better understand the 
molecular basis of melanoma initiation and progression, but importantly it allows to 





Figure 1.5 Signaling pathways altered in melanoma (Hocker et al., 2008). 
 
1.1.3.1  The RAS/RAF/MEK/ERK cascade 
Melanoma can originate from malignant transformation of melanocyte (75% of the 
cases) or from melanocytic naevi (25% of the cases), that may be congenital or appear 
throughout the life (acquired). Nevi are benign proliferations of melanocytes, with a 
very low likelihood of progressing to melanoma (Shain et al., 2016). At a molecular 
level, the first step in melanomagenesis is the abnormal proliferation of melanocytes 
sustained by an uncontrolled activation of the mitogen-activated protein kinase (MAPK) 
signaling pathway. Aberrant activation of this pathway is the result of somatic 
mutations of N-RAS, associated with about 15% of melanomas, or BRAF, present in 
about 50% of melanomas (Davies et al., 2002). These mutations, which are mutually 
exclusive, cause constitutive activation of the serine–threonine kinases in the MEK 
(mitogen-activated protein kinase)/ERK (extracellular signal-regulated kinase) pathway. 
Both RAS and BRAF are important mediators of the response to extracellular stimuli, 
including those of the UV rays, and play a central role in regulating cell growth, 
13 
 
survival and proliferation. After UVR exposition, the photoprotection induce not only 
the skin pigmentation but also the proliferation of melanocytes to increase the melanin 
production (Mar et al., 2013).  
RAS gene family products belong to the small GTPase family, small proteins 
bound to the cytoplasmic membrane and involved in the intracellular transduction of a 
plethora of signals. In melanoma, NRAS is the most commonly mutated isoform 
compared to the other members of the same family (HRAS and KRAS) that are almost 
never involved. NRAS is mutated in 33% of primary melanomas and 26% in metastatic 
melanoma. The mutation consists in a substitution of a Glutamine with Arginine, Lysine 
or Leucine in position 61 (NRASQ61K/R). This mutation impairs the GTP hydrolysis, 
resulting in a constitutionally activated NRAS. Oncogenic stimulation of NRAS is able 
to activate two important signaling pathways, thus regulating RAF and PI3K 
(Phosphatidylinositol 3-Kinase). The RAS-RAF-MEK-ERK pathway is involved in 80-
90% of melanomas through mutations on different members (Ghosh et al., 2009). 
RAF is a serine threonine kinase which acts as a downstream effector of RAS in 
the MAPK signaling pathway. The RAF kinase family consists of three proteins 
(ARAF, BRAF and CRAF), expressed in various human tissues. Several alternative 
splicing forms are known for BRAF gene, giving rise to at least 10 protein isoforms 
expressed in a variety of tissues. Forthy-three probable mutations with potential 
oncogenic activity were described, all located in exons 11 and 15 (Hall et al., 2014). In 
melanoma, the BRAF gene is mutated in 40-60% of cases (Devies et al., 2002). The 
prevalent mutation (about 90% of cases) is represented by the replacement of a Valine 
with Glutamic acid at codon 600 (BRAF-V600E). The BRAF-V600E variant induces a 
continuous stimulation of cell proliferation and tumor growth through a constitutive 
ERK activating phosphorylation (Shtivelman et al., 2014). BRAF-V600E is the most 
common initiating mutation in melanomas. However, in human 81% of melanocytic 
nevi harbor NRASQ61K/R mutation and 82% of acquired nevi harbor BRAF-V600E 
mutation. The identification of activating BRAF mutations in benign nevi indicates that 
its oncogenic activation is a necessary condition in tumor initiation but is not sufficient 
for melanoma development. In absence of other driver mutations, the mutant BRAF-
V600E results in a limited expansion of melanocytes to form a common naevus. These 
nevi remain as stable lesions that are probably composed of a mixture of permanently 
arrested (senescent) cells and slowly proliferating cells, evading the immune cell-
mediated control. In human melanocytes, mutant BRAF protein induces cell senescence 
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by increasing the expression of the cell cycle inhibitor of kinase 4A (INK4A) and ARF 
activity on p53 degradation. This mechanism appears as protective reaction in response 
to the activation of an uncontrolled mitogenic signal (Pollock et al., 2003). The arrest of 
the cell cycle caused by INK4A can, however, be overcome by mutations in INK4A 
itself, as well as other cell cycle factors. Indeed, the expression of INK4 is reduced or 
absent in about 1/3 of melanomas with BRAF-V600E mutation (Pollock et al., 2003).  
 
1.1.3.2  Additional pathways deregulated during melanoma progression 
Benign nevi must acquire additional molecular alterations to progress towards an 
invasive phenotype. The molecular abnormalities at this stage of progression affect cell 
growth, DNA repair and the susceptibility to cell death. The PI3K/AKT signaling 
pathway is involved in cell proliferation and in the apoptosis, through the inhibition of 
many proapoptotic proteins, such as BAD (antagonist of BCL-2, which hinders the 
mechanisms of cell death) and the activation of MDM2 (responsible of p53 
degradation). The PI3K/AKT signaling pathway is deregulated in advanced melanoma 
stage. Indeed, PTEN loss is found at high frequency (about 37%) in melanomas, but not 
in nevi. The levels of other components of PI3K pathway, such as AKT, increase during 
melanoma development. PTEN loss allows the bypass of senescence induced by 
p16INK4a loss and triggered activation of the PI3K/AKT proliferative signaling, 
supporting melanoma progression (Shull et al., 2012). Once malignant neoplastic 
proliferation has begun, further mutations induce the acquisition of invasion and 
metastatic capacity. The PI3K/AKT signaling pathway promotes the plasticity of cancer 
cells by controlling epithelial mesenchymal transition (EMT). This pathway regulates 
expression and activity of factors involved in cell motility, such as RAC1, and 
degradation of components of basal laminae, such as the metalloproteases MMP-9, 
allowing melanoma cells to invade the underlying dermis (Larue et al., 2005).  
In some melanomas, MAPK and PI3K pathway dysregulation results from 
overexpression or hyperactivation of growth factor receptors, such as c-KIT, EGFR or 
inactivating mutations in neurofibromin 1 (NF1), a negative regulator of Ras 
(Krauthammer et al., 2015). Activating mutations in GNAQ and GNA11, two G protein 
α-subunits involved in MAPK signaling, are identified in particular in the uveal 
melanomas. Other important pathways deregulated in melanoma are the Wnt/β-catenin 
pathway, which seems to contribute to the inhibition of apoptosis in melanoma 
progression, and the Hedgehog pathway, which will be further discussed later (Lo et al., 
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2014). The frequency of p53 mutations is lowest in melanomas compared to other 
cancers. Only 1-5% of primary melanoma and 11-25% of metastatic melanoma show 
mutations or deletions of TP53. Furthermore, it has recently been shown that the tumor 
microenvironment (altered distribution and chemokine concentration, non-activation of 
cell-mediated immunity, induction of immunosuppressive mechanisms) and immune 
system play an important role in the formation and maintenance of melanoma 
metastases melanoma (Regad, 2013).  
This complex mutational landscape shows that melanoma is characterized by 
different types of gene alterations, flowing into the deregulation of RAS-RAF-MEK-
ERK and PI3K-AKT pathways. Interestingly, mutations of NRAS and BRAF or NRAS 
and PTEN are mutually exclusive. PI3K pathway mutations are present in 9% of NRAS 
mutant tumors. Co-occurrence of BRAF and PTEN mutations was reported in 17% of 
melanomas. This is probably because NRAS is able to activate both pathways, while 
BRAF leads to the activation of the only RAS-RAF-MEK-ERK pathway and confirm 
the need to other mutation in addition to BRAF for melanoma progression (Miller et al., 
2006). 
Other genes involved in melanoma, including familial melanoma that represents 
8-12% of the total number of cases, are CDKN2A and CDK4.The CDKN2A (Cyclin-
Dependent Kinase Inhibitor 2A) is mutated in 20-40% of familial melanoma and 
encodes two tumor suppressor proteins, p16INK4a and p14ARF (Alternative Reading 
Frame). p16INK4A inhibits Cdk4/6-mediated phosphorylation of the retinoblastoma 
protein (Rb). In the hypophosphorylated state, Rb binds and represses the E2F 
transcription factor and prevents G1 to S phase transition in cell cycle. On the other 
hand, p14ARF directly prevents p53 degradation by the E3 ubiquitin protein ligase 
MDM2 (Mouse Double Minute 2). In physiological conditions, CDKN2A appears to 
play a central role in preventing cancer formation by mediating a senescence-like state 
upon oncogenic stress. In melanoma, the loss of ARF and INK4 activity promotes the 
proliferation of tumor cells and involves the reduction of p53 protein levels. 
Consistently, activating mutations of BRAF and loss of functional p16INK4a and 
p14ARF were detected in the majority of melanomas. Furtheremore, oncogenic 
mutations in NRAS require concomitant loss of CDKN2A in order to progress 
melanoma (Nelson et al., 2009). 
The gene encoding cyclin dependent kinase 4 (CDK4A) is involved in a very 
small percentage of familial melanoma. The mutation of arginine at position 24 into 
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cysteine (CDK4R24C) or histidine (CDK4R24C) renders the protein insensitive to 
regulation by p16INK4a. This results in a constitutive activation of the complex with 
the Cyclin D and aberrant proliferation, through Rb inactivation and E2F1 activation. 
CDK4R24C facilitates tumorigenesis of melanocytes transplanted into nude mice and 
causes escape from cellular senescence (Chin et al., 2003). In addition to these family 
forms, a number of genes involved in the pigmentation of the skin are related to 
moderate susceptibility to melanoma development. MC1R (Melanocortin-1 Receptor) 
is a seven-domain trans-membrane domain coupled to protein G. The a-MSH binding 
promotes the increase in cyclic AMP levels, which promote the activity of MITF, a 
factor that controls the transcription of genes involved in melanin production. Some 
MC1R genetic variants are not able to stimulate an appropriate production of melanin, 
whose job is to defend the skin against the ultraviolet rays damage. The presence of 
these MC1R variants in combination with intermittent exposure to solar ultraviolet rays 
is considered to be responsible for BRAF oncogenic activation by increasing 
intracellular AMP cyclic levels (Tsao et al., 2012). Finally, MITF (Microphthalmia-
associated Transcription Factor) is amplified in 20% of melanoma patients and 
represent a negative prognostic factor. MITF controls genes involved in cell cycle 
regulation, such as CDK2, or antiapoptotic genes belonging to the BCL2 family, which 
are amplified in 30% of melanomas. HIF1α is also a target of MITF: in the presence of 
MITF amplification, expression of HIF1α is increased and promotes survival, 
angiogenesis and metastasis (Dahl et al., 2007). 
The recent knowledges and discoveries on the molecular mechanisms involved 
in melanoma pathogenesis and progression are fundamental to identify markers able to 
predict both prognosis and therapeutic response to specific treatments in melanoma 
patients. 
 
1.1.4 Targeted therapy in melanoma 
The possibility to efficaciously treat melanoma depends to the tumor stage at diagnosis. 
Early-stage primary melanoma can be successful treated through surgery, which often 
eradicates the lesions localized to the skin with a 10-year survival of 95% of patients. 
The prognosis is poor for patientswith metastatic melanoma, with a median survival of 
about 10% of patients at 5 years (Ugurel et al., 2017). 
The treatment of metastatic melanoma has seen fundamental improvements in 
recent years. Novel treatment strategies, based on targeted therapy and immunotherapy, 
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have as main goal the induction of a long-term therapeutic response to significantly 
improve survival of patients. Before the approval of targeted and immune terapies, 
conventional chemotherapy was based on the use of alkylating agents such as 
dacarbazine (Deticene) and IL-2, a cytokine approved by the Food and Drug for 
melanoma therapy in US. However, only 5% of patients showed an objective response 




Figure 1.6 Important therapeutic targets in melanoma and the key inhibitors for melanoma therapy 
(Cosgarea et al., 2017). 
 
The identification of the molecular alterations at the basis of melanoma, 
particularly in the MAPK signaling pathway, and the possibility to block specific targets 
with specific inhibitors has significantly broadened the therapeutic horizon and radically 
improved the therapeutic outcome. In targeted therapy, the characterization of the 
mutational profile of melanoma patients is crucial to choose the better therapeutic 
approach (Van Allen et al., 2014). Because of its prevalence in 50% of all melanomas, 
BRAF-V600E is an oncogenic driver in this tumor and so a key target for melanoma 
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therapy. The first targeted therapy to demonstrate substantial efficacy against melanoma 
was Vemurafenib, an ATP-competitive BRAF-V600E inhibitor (Chapman et al., 2011). 
In recent years, different clinical trials have shown successful inhibition of the MAPK 
signaling pathway through new highly selective BRAF inhibitors Dabrafenib 
(GSK2118436) and Encorafenib (Cosgarea et al., 2017).  
The treatment of BRAF mutated metastatic melanomas is associated with a rapid 
therapeutic response in 50–80% of patients as well as a prolonged progression-free 
survivalof 6–10 months and an overall survival of 16–20 months (Chapman et al., 
2011). Based on these successful clinical trials, Vemurafenib and Dabrafenib have been 
approved in the USA and Europe for the treatment of BRAF-V600 mutated metastatic 
melanoma. The approval is still pending for Encorafenib. However, BRAF inhibition is 
not effective in the remaining 50% of BRAF wild-type melanomas, including NRAS 
mutated tumors (NRASQ61). The treatment of non-mutant BRAF cells with Dabrafenib 
or Vemurafenib would result in a paradoxical activation of the MAPK pathway, 
mediated by CRAF (Poulikakos et al., 2010). MEK inhibitor treatment is the only 
targeted therapy for patients with NRAS-mutated melanoma or wild type BRAF with 
effective results in clinical trials. Also for MEK inhibitor, resistance has been reported 
to arise as a result of mutations in the allosteric drug binding pocket or amino-terminal 
negative inhibitory domain (Das Thakur et al., 2014; Grossman et al., 2001). 
BRAF inhibitor monotherapy is not only associated with a rapid therapeutic 
response but also with the development of resistance within 5–6 months (Wagle et al., 
2011). Multiple mechanisms have been reported for BRAF and MEK inhibitor 
resistance, including upregulation of receptor tyrosine kinase (RTK) signaling, 
activation of NRAS signaling, amplification of BRAF (Corcoran et al., 2010), 
alternative splicing of mutant BRAF, emergence of mutations in RAS or MEK 
concurrently with mutant BRAF (Emery et al., 2009). All the listed resistance 
mechanisms lead to the reactivation of the MAPK signaling at different levels or to the 
activation of parallel signaling pathways (Haarberg et al., 2013). To prevent the 
reactivation of a proliferative signaling, the combination of inhibitors targeting different 
signaling pathways has become an attractive option, not only to enhance the therapeutic 
effectiveness but above all to delay the onset of resistance. The combination of 
BRAF/MEK inhibitors (Dabrafenib and Trametinib) as a strategy to mitigate acquired 
BRAF inhibitor resistance is clinically effective and was recently approved by the FDA 
for BRAF-mutant melanomas (Voskoboynik et al., 2014; Volpe et al., 2017). This 
19 
 
therapeutic strategy allows to delay tumor progression, but still does not impair the 
onset of different mechanism of resistance associated with adirect reactivation of the 
final kinase of the MAPK pathway, ERK1/2 (Samata et al., 2014). SCH772984 is a 
potent and selective ERK1/2inhibitor that blocks both ERK kinase activity and its 
phosphorylation by MEK. SCH772984 shows a strong activity in patients with BRAF, 
NRAS and KRAS mutant tumors, reducing tumor progression and cell proliferation at 
nanomolar concentrations also in resistant tumor cells (Morris et al., 2013). However, a 
long-term exposure of cells to SCH772984 leads to acquired resistance due to a 
mutation of glycine to asparticacid (G186D) in the Asp-Phe-Gly “DFG”motif of ERK1. 
The conserved DFG motif is conteined in a pocket adjacent to the ATP binding region 
and it coordinates the binding of magnesium, which is essential for enzyme catalysis 
and phosphotransfer (Jha et al., 2016). 
In conclusion, although the significant progresses in the melanoma targeted 
therapy field, a major challenge continues to be forestalling the emergence of resistance. 
This reveals an urgent need to identify new therapeutic targets to improve the survival 




1.2 The MEK5/ERK5 pathway 
The MAPK (Mitogen Activated Protein Kinase) family is one of the most conserved 
and expressed extracellular signal transduction pathways in eukaryotes. Different 
stimuli, including internal metabolic stress, as well as external mitogens, hormones, or 
neurotransmitters, cell–matrix and cell–cell interactions, lead to the initiation of a 
phosphorylation cascade culminating in the activation of a final acting MAPK, which 
transduces the signal into the nucleus. The members of the MAPK family are involved 
in essential cellular processes such as proliferation, differentiation, migration and 
apoptosis (Pearson et al., 2001). The importance of the MAPK pathways is highlighted 
by the observation that their constitutive activation is frequent in multiple human 
cancers, in particular in melanoma. Three atypical MAPK subfamilies have been 
identified: ERK3 and ERK4, ERK8 (also known as ERK7) and Nemo-like kinase-NLK. 
The four conventional MAPK subfamilies include extracellular signal-regulated protein 
kinases 1/2 (ERK1/2); c-Jun N-terminal kinases 1–3 (JNK1, 2 and 3); p38 MAPKs (α, 
β, γ and δ p38); and the most recently discovered ERK5 (Cargnello et al., 2011). 
The MEK5/ERK5 pathway is the lesser studied among the MAPK pathway 
members and presents unique structural and functional features distinct from other 
MAPKs. These peculiar characteristics and the relevance in important cellular functions 
make this kinase an interesting target for future therapeutics interventions.  
The ERK (extracellular-signal-regulated kinase) 5 protein is the effector kinase 
of a canonical three-tiered MAPK signalling cascade comprising MEKK (MEK kinase) 
2/3, MEK (MAPK/ERK kinase) 5 and ERK5 itself. In response to different stimuli, 
MEKK2/3 binds the N-terminal domain of MEK5 and activates MEK5 by Ser311 and 
Thr315 phosphorylation. MEK5 protein kinase, encoded by MAP2K5, remains the only 
known MEK that directly activates ERK5. Alternative splicing results in two isoforms 
of MEK5 (50 kDa α and 40 kDa β) differing in their relative binding affinities for 
ERK5. MEK5α is a stronger activator of ERK5 than MEK5β, which lacks the 
consensus motif crucial to ERK5 binding and complete activation (Hoang et al., 2017). 
The MEK5 activated form binds to the N-terminal domain of ERK5 and phosphorylates 
two residues in the TEY sequence, which is similar to the binding sites of ERK1 and 
ERK2. The dual phosphorylation on Thr218 and Tyr 220 activates ERK5, inducing 
nuclear translocation (Nithianandarajah-Jones et al., 2012). Known substrates of ERK5 
include the transcription factors Sap-1a, c-FOS, c-MYC and MEF2 family members (A, 
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C and D), as well as kinases, such as ribosomal s6 kinase (RSK) and 
serum/glucocorticoid-regulated kinase (SGK). 
 
 
Figure 1.7 MAPK signaling cascade in mammalian cells (Nithianandarajah-Jones et al., 2012). 
 
 
1.2.1 ERK5 structure and regulation 
ERK5 is encoded by the MAPK7 gene, which was first identified and cloned in two 
independent studies two decades ago (Zhou et al., 1995; Lee et al., 1995). ERK5, also 
named Big Mitogen Kinase 1 (BMK1), comprises 816 amino acid (aa) residues and is 
more than twice the molecular weight (110 kDa) compared to the other MAPK family 
members. Structurally, ERK5 protein contains a N-terminal domain (amino acids 1–
406), which is important for the kinase activity, and a large C terminus of 410 amino 





Figure 1.8 ERK5 structure and functions (Modified from Nithianandarajah-Jones et al., 2012). 
 
The N-terminus presents a region required for cytoplasmic targeting (a.a. 1–77), 
followed by a kinase domain (a.a. 78–406) which shares 66% sequence identity to the 
kinase domain of ERK2. In the kinase domain there is also a region essential for MEK5 
interaction (a.a. 78–139) and for oligomerisation (a.a. 140–406). ERK5 N-terminal 
region presents a common docking (CD) domain, consisting of a short sequence of 
negatively-charged amino acid residues (a.a. 350–358) important for the association 
with substrates containing docking domain. ERK5 differs from other members of the 
MAPK pathway for the presence of a unique C-terminal domain, which contains a 
nuclear localization sequence (NLS, a.a. 505–539) important for ERK5 nuclear 
targeting; two proline-rich domains, PR1 (a.a. 434–465) and PR2 (a.a. 578–701), 
considered potential binding sites for proteins containing Src-homology 3 (SH3)-
domain; and a region for the interaction with the myocyte enhancer factor 2 (MEF2) 
(a.a. 440–501) (Nithianandarajah-Jones et al., 2012). A potent transcriptional activation 
domain (TAD) (a.a. 664–789) was identified in the C-terminus of ERK5 (Kasler et al., 
2000), through which ERK5 can bind and activate several transcription factors. ERK5 
C-terminal domain presents different residues which undergo autophosphorylation by 
the activated ERK5 itself (Morimoto et al., 2007) or other kinases. The phosphorylation 
on this region is crucial to regulate ERK5 activity and nuclear localization. 
ERK5 is located both in the cytoplasm and in the nucleus. In basal conditions, 
the inactive form of ERK5 is retained in the cytoplasm, where it is associated with the 
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co-chaperone Cdc37 and the chaperone Hsp90, which ensures the cytosolic anchorage 
of the ERK5 protein. The trimeric complex ERK5-Hsp90-Cdc37 stabilizes ERK5 in an 
inactive conformation that facilitates the MEK5 recognition and activation. In the 
unphosphorylated inactive form, the N- and C-terminal domains are bound causing a 
folding structure that hides the nuclear localization sequence (NLS), promoting 
cytoplasmic retention. In the folded structure, the C-terminal tail masks the CD domain 
in N-terminus, preventing the interaction of ERK5 with its substrates. The MEK5 
phosphorylation on the TEY region initiates the kinase activity of ERK5, that can 
phosphorylate the C-terminal residues of the protein, promoting the release of Hsp90 
from the complex. ERK5 can assume an open conformation, exposing the NES 
sequence that promotes the nuclear translocation (Gomez et al., 2016). 
 
 
Figure 1.9 Nucleo-cytoplasmic mechanisms of ERK5 translocation (Gomez et al., 2016). 
 
According to this model, the phosphorylation of the C-terminal region is required for 
the maximal transactivator activity of ERK5, that is exerted through its nuclear 
localization and the phosphorylation of nuclear targets. It has been shown that gradual 
truncation of this C-terminal tail gives rise to increased kinase activity of ERK5, 
suggesting that the tail has an autoinhibitory function. Furthermore, the phosphorylation 
in this region may influence also the nucleo-cytoplasmic shuttling of the protein. 
Although full length ERK5 mainly resides in the cytoplasmic compartment and only 
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partially in the nucleus, the truncation of the last 100 amino acids results in the nuclear 
accumulation (Buschbeck et al., 2005). Based on these structural features, the kinase 
activity of ERK5 seems to have two roles in gene expression: the activation of 
transcription factors by direct phosphorylation and the enhancement of the ERK5 
transactivator activity by, presumably, autophosphorylation of its C-terminal-half 
(Morimoto et al., 2007).  
Recently, novel MEK5-independent mechanisms of ERK5 activation and nuclear 
translocation have been described. It has been shown that nuclear ERK5 devoided of the 
kinase activity is able to activate transcription (Borges et al., 2007). Once in the 
nucleus, ERK5 enhances gene transcription by either phosphorylating transcription 
factors or by interacting with these factors through the transactivation TAD domain 
located at the C-terminal. Therefore, ERK5 nuclear shuttling requires only C-terminal 
phosphorylation that may be promoted through the ERK5 autophophorylation or by 
other kinases. During mitosis, ERK5 phosphorylation is sustained by cyclin-dependent 
kinase 1 (CDK1), which is important for the G2/M cell cycle transition. Four different 
residues on C-terminal domain may be phosphorylated during mitosis (Ser753, Thr732, 
Ser773, Ser706) (Figure 1.8) and these are important for ERK5 nuclear localization of 
the kinase (Díaz-Rodríguez et al., 2010; Iñesta-Vaquera et al., 2010). Another important 
residue in C-terminal domain is Thr732, which is phosphorylated by CDK1 and also by 
ERK1/2. This event induces ERK5 nuclear localization and promotes ERK5-dependent 
transcription, without affecting the phosphorylation status at TEY or other C-terminal 
residues. Treatment with a selective MEK1/2 inhibitor (U0126) reduces the Thr732 
phosphorylation, suggesting that ERK1/2 can mediate the phosphorylation of ERK5 at 
Thr732 (Honda et al., 2015). 
Beyond the cellular localization and C-terminal phosphorylation, ERK5 activity is 
regulated by further mechanisms. Three ERK5 splice variants have been identified in 
mouse (mERK5a, mERK5b and mERK5c): mERK5b and mERK5c, that lack the 
protein kinase activity, function as dominant negative kinases blocking mERK5a 
activity and ERK5-mediated MEF2C activation (Hoang et al., 2017; Yan et al., 2001). 
The duration and the magnitude of MAPK activation are tightly regulated, to assure a 
physiological and not aberrant signaling. The protein Ser/Thr phosphatases PP1/PP2A 
(Garcia et al., 2002) and tyrosine-specific phosphatases (PTPs) not only block the 
ERK5 activation but also effectively impede the translocation of ERK5 to the nucleus 
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(Buschbeck et al., 2002). Finally, the dual-specificity protein phosphatase DUSP5 and 
DUSP6 regulate the dephosphorylation of the TEY motif (Arkell et al., 2008). 
 
1.2.2 Role of ERK5 in physiological conditions 
In physiological conditions ERK5 is ubiquitously expressed in many tissues, 
particularly in the brain and the heart. During development, it plays an essential role in 
the formation of cardiac tissue and blood vessels and is an important mediator of 
survival signals in nervous system cells. Genetic deletion of ERK5 is embryonic lethal 
and tissue-restricted deletions have profound effects on erythroid development, cardiac 
function, and neurogenesis (Hayashi et al., 2004). In adults, it remains active as an 
important regulator of proliferation and survival, especially in endothelial (Roberts et 
al., 2009) and immune system cells (Rovida et al., 2008). Initially, ERK5 was identified 
as a MAPK activated by environmental stresses, such as oxidative and osmotic stress, 
UV rays, etc. Further studies show that ERK5 is physiologically involved in the 
response to different stimuli. It is activated by a range of growth factors, including 
vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), fibroblast 
growth factor (FGF), platelet-derived growth factor (PDGF), brain-derived neurotrophic 
factor (BDNF), nerve growth factor (NGF) as well as by cytokines, such as leukaemia 
inhibitory factor (LIF) and interleukin 6 (IL-6) (Simões et al., 2016). The MEK5/ERK5 
signalling pathway has been implicated in the regulation of several cellular processes, 
including differentiation, proliferation, survival, antiapoptotic signaling and 
angiogenesis. The identification of downstream effectors of the ERK5 pathway is 
important to understand its physiological function. The best-characterized ERK5 
substrates are the three members of the myocyte enhancer factor (MEF) family of 
transcription factors. ERK5 plays a crucial role in cell proliferation, inducing the 
transcription of c-jun through the MEF2C transcriptional activation (Kato et al., 1997) 
in response to serum or EGF stimulation. Activation of ERK5 pathway induces 
phosphorylation and stabilization of c-Fos and Fra-1 transcription factors (Lochhead et 
al., 2012). ERK5 regulates cell cycle progression, in particular the G1/S transition. 
ERK5 promotes an activating phosphorylation of the serum and glucocorticoid-induced 
kinase (SGK), which promotes the entry into S phase in response to growth factors. 
Different studies demonstrate that ERK5 suppresses the expression of the cyclin 
dependent protein kinase (CDKs) inhibitors p21 and p27 (Perez-Madrigal et al., 2012), 
promoting cell proliferation. Moreover, ERK5 regulates the expression of the cyclin D1, 
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involved in a key cell proliferation checkpoint and frequently deregulated in cancer 
(Wang et al., 2006). ERK5 promotes also the G2/M transition, activating the 
transcription factor NF-kB, which upregulates genes involved in mitosis such as cyclin 
B1 and B2 and Cdc25B. During mitosis, ERK5 is involved in cell survival. Indeed, 
ERK5 prevents caspase activation by binding the pro-apoptotic protein Bim. ERK5 
contributes to the survival response in neuronal dorsal root ganglia cells mediating the 
nerve growth factor (NGR) signaling system. In this pathway, a phosphorylation 
cascade mediated by ERK5 results in the activation of p90 ribosomal S6 kinase (RSK), 
which has as ultimately target the Ca2+/cAMP response element binding protein 
(CREB) (Ranganathan et al., 2006). CREB regulates the transcription of pro-apoptotic 
and survival genes. Further studies indicate that ERK5 contributes to survival in 
neurons via activation on transcription factor MEF2, a pro-survival and anti-apoptotic 
transcription factor (Drew et al., 2012). 
 
1.2.3 Role of ERK5 in cancer 
Since its discovery, ERK5 activity and regulation has been studied in cancer because of 
its implication in essential cellular functions, associated with “the hallmarks of cancer” 
(Lochhead et al., 2012).  
 
Figure 1.10 The MEK5/ERK5 signaling pathway in tumor cells regulates proliferation, survival, 
apoptosis and metastatic processes through a complex intracellular signaling system (Drew et al., 2012). 
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Alterations in the activity and expression of different members of the 
MERK5/ERK5 pathway seem to be directly involved in various types of cancer. In 
breast cancer, MEK5 expression is upregulated by constitutive activation of STAT 
(signal transducer and activator of transcription) 3 that is frequent in patients with 
advanced breast cancer compared to normal breast epithelial cells (Liu et al., 2017). 
Furthermore, increased ERK5 protein levels in either TNBC or in HER2+ patients 
correlate with poorer relapse-free survival (Montero et al., 2009; Ortiz-Ruiz et al., 
2014). In prostate and colon cancers, MEK5 and ERK5 are overexpressed and correlate 
with the presence of bone metastases. The acquisition of a more aggressive and 
metastatic phenotype correlates with less favorable prognosis (Ramsay et al., 2011; 
Simões et al., 2016). Furthermore, an ERK5 gene amplification has been identified at 
17p11 in approximately 50% of primary hepatocellular carcinomas (HCC). 
Consistently, in patients with HCC ERK5 is more abundantly expressed in the nucleus 
compared with normal liver tissue. Genetic or pharmacological inhibition of ERK5 
reduces proliferation, migration and invasiveness of HCC cells. Moreover, ERK5 
silencing decreases the growth of HCC xenografts (Rovida et al. 2014). 
Clinical evidences show that an increase in MEK5/ERK5 signalling may be 
important for tumor initiation, metastatic progression and drug resistance. ERK5 is 
responsible for proliferative signaling sustaining the initial stage of cancer through the 
regulation and induction of cell cycle regulators, including cyclin D1, c-MYC, n-MYC, 
SGK, RSK2 and NF-kB. Through phosphorylation of MEF2 transcription factors, 
MEK5 has been shown to regulate the expression of c-JUN, a proto-oncogene essential 
to cell growth. Moreover, ERK5 can mediate also a survival signaling used by cancer 
cells to escape apoptosis. In endothelial cells MEK5 activation is responsible for 
activation of NF-kB and inhibition of caspase 3, resulting in apoptosis inhibition. ERK5 
also regulates the activity of transcription factors involved in survival, such as CREB 
and MEF-2 (Pi et al., 2004). In cancer cells, ERK5 interacts with the promyelocytic 
protein (PML) and inhibits its tumor suppressor activity. ERK5 mediated- 
phosphorylation of PML induces the dissociation by MDM2, downregulating the 
expression of p53 tumor suppression (Yang et al., 2013). ERK5 can sustain cancer cells 
proliferation not only through the deregulation of its pathway, but also by non-canonical 
mechanisms. In some cancer types, ERK5 shows a constitutive nuclear localization 
mediated by the overexpression of Cdc37, which induces the release of the ERK5 
cytoplasmic chaperone Hsp90 and the nuclear shuttling of the kinase. Cdc37 acts as an 
28 
 
oncogene, stabilizing other important mediators of cancer proliferation, such as Akt, 
BRAF and HER-2 (Gomez et al., 2016). Several studies in literature show that silencing 
or pharmacological inhibition of ERK5 is able to delay cell cycle progression and to 
reduce proliferation in several types of cancer. However, there are some conflicting 
reports that challenge the role of ERK5 in cell proliferation (Giurisato et al., 2016; Lin 
et al., 2016). Among these, a recent study shows that colon cancer cells with KRAS or 
BRAF mutations do not require ERK5 activity for proliferation at least in vitro 
(Lochhead et al., 2016).  
Deregulation of ERK5 pathway is important also in tumor progression and is 
associated with metastatic risk in prostate, breast, colon, kidney, bone, and oral cancers, 
with less favorable survival outcome. The MEK5/ERK5 pathway is involved in cellular 
motility and can therefore play a role in the EMT, one of the key processes in tumor 
progression towards a metastatic phenotype. It has been shown that transcription of 
some key genes in EMT (such as Twist, ZEB, Snai2) is under the control of the 
MEK5/ERK5 pathway (Drew et al., 2011). Moreover, ERK5 is able to form complexes 
with the αvβ3 integrin and interact with Focal Adhesion Kinase (FAK) to regulate the 
organization of the cytoskeleton, thus participating in adhesion and motility processes 
(Sawhney et al., 2009). MEK5 promotes the expression of some extracellular matrix 
(ECM) metalloproteases, which degrade ECM promoting the migration and metastasis 
of tumor cells. An experimental system in melanoma A375 cells and prostate cancer 
demonstrates the ERK5 involvement in the formation of invadopods, cellular cell 
protrusions that allow migration during metastasis (Ramsay et al., 2011). 
Although activating mutations in ERK5 have not been reported so far, the 
MEK5/ERK5 pathway is altered in several types of cancer. The pathway is under the 
control of several oncogenes, including RAS, RAF, Src, EGF, VEGF, COT, that 
promote up-regulation of different downstream MAPKs, including ERK5. COT is a 
protein kinase involved in the oncogenic transformation of NIH3T3 fibroblasts through 
a mechanism mediated by a cooperative signal with ERK5 (Chiariello et al., 2000). 
Oncogenic variants of Src seem to be involved in the activation of ERK5 pathway in 
fibroblasts, resulting in a transition to an invasive and metastatic phenotype. It would 
appear that the ERK5 pathway is involved in the transduction of the oncogenic effects 
of RAS and RAF, which are mutated in most tumors (Nithianandarajah-Jones et al., 
2012). Independently of upstream regulators, also other parallel pathways can mediate 
the deregulation of ERK5 signaling, acting directly on ERK5. The MEK5/ERK5 
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pathway is one of the alternative pathways reactivated upon chemotherapy, conferring 
drug resistance to cancer cells. A recent report showed that ERK5 phosphorylation is 
enhanced in melanoma cells resistant to the combined inhibition of BRAF and MEK1/2 
(CIBM), which is the current approach used in therapy. Silencing or pharmacological 
inhibition of ERK5 impairs the acquisition of resistance to CIBM and sensitizes cancer 
cell to chemotherapy, restoring the antiproliferative effect of the chemotherapy. The 
activating phosphorylation of ERK5 in response to CIBM therapy seems to be sustained 
by a SRC/MEK5 cascade, probably activated upstream by BRAF (Song et al., 2017). 
 
 
Figure 1.11 Drug resistance to combined inhibition of BRAF and MEK1/2 is mediated by ERK5/BMK1 
through SRC/MEK5 cascade (Song et al., 2017). 
 
The emerging key role of the MEK5/ERK5 pathway in several physiological 
processes and in oncogenesis highlights its potential as target in novel cancer 
therapeutic strategies. 
 
1.2.4 ERK5 inhibitors: clinical relevance 
In recent years interest in developing inhibitory molecules against ERK5 activation and 
function has emerged, due to the crucial role of ERK5 in tumorigenesis and in drug 
resistance. The first strategy for ERK5 pathway inhibition is based on the use of 
microRNAs, particularly miR-143 and miR-145, that physiologically act as tumor 
suppressors by regulating ERK5 expression levels. In bladder and prostate tumors, the 
reduced expression of miR-143 seems to be correlated with the high levels of ERK5. 
The treatment of these tumor cell lines with synthetic analogs of miR-143 and miR-145 
shows a reduction in cells proliferation and ERK5 protein levels comparable to the 
results observed with RNA interference or ERK5 knockdown. However, different 
studies are still underway to verify that this antitumour activity of these synthetic 
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miRNAs is due to the selective binding on ERK5, which can also act on different 
cellular substrates (Clapé et al., 2009¸ Zhou et al., 2017). 
Pharmacological molecules actually available for the MEK5/ERK5 signaling 
inhibition target the central kinases of the pathway (Figure 1.12). 
 
 
Figure 1.12 Pharmacological inhibition of the MEK5/ERK5 pathway. BIX02189 targets the 
MEK5, whereas XMD8-92 inhibits the ERK5 kinase activity (Nithianandarajah-Jones et al., 
2012). 
 
The first inhibitors described for the ERK5 pathway were the indolinone-6-
carboxamides BIX02188 and BIX02189 (Boehringer Ingelheim Pharmaceuticals). 
These small-molecules compete for the ATP binding site in the MEK5 catalytic domain, 
blocking its kinase activity with IC50 4.3 and 1.5 nM, respectively. BIX02189 also 
displayed more potent suppression of ERK5 kinase activity with IC50 59 nM compared 
to that of BIX02188 (810 nM). Both compounds also inhibited transcriptional activity 
of MEF2, the downstream substrate of the MEK5/ERK5 signaling cascade, in a dose-
dependent manner. These MEK5 inhibitors blocked ERK5 phosphorylation without 
affecting activation of ERK1/2, p38 MAPK, or JNK (Tatake et al., 2008). According to 
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a recent study, BIX02189 reduces TGF-β1-induced EMT, cell motility and expression 
of matrix metalloproteinase-2. BIX02189 strongly blocks the activation of TGF-β1 
signaling components independently of MEK5, demonstrating a direct activity on TGF-
β1 for BIX02189 (Park et al., 2016). 
Furthermore, ERK5 autophosphorylation in its C-terminal domain is 
fundamental for its activity and nuclear translocation and has been revealed to have a 
significant influence on the response of cancer cells to chemotherapeutic agents. For 
these reasons, the inhibition of the final effector of the pathway seems to be a better 
strategy for clinical application. The benzopyrimido-diazepinone XMD 8-92 is a 
competitive inhibitor of ATP-site in ERK5 kinase domain, ensuring a total inhibition of 
ERK5 kinase activity that can no longer phosphorylate either its cellular substrates or 
itself at the level of the C-terminal domain. To validate the specific activity of XMD8-
92 on ERK5, an inhibition profiling of the compound was performed first against a 
diverse panel of 402 kinases and then against all detectable kinases in HeLa cell line. 
XMD 8-92 is able to inhibit the ERK5 activation mediated by EGF and significantly 
reduces ERK5-dependent MEF2C-driven gene expression. No activity against ERK1/2 
and MEK5 are observed (Yang et al., 2010). In vivo, the IP administration of 50 mg/kg 
dose of XMD8-92 is efficacy in controlling tumor growth and inflammation with good 
pharmacokinetics, bioavailability and tolerability (Al-Ejeh et al., 2014). Beyond the 
promising clinical results obtained with ERK5 chemical inhibition, its clinical 
application is compromised by the recently discovered role in the direct inhibition of 
bromodomains (BRDs) (Lin et al., 2016). Although in several studies the results 
generated through XMD8-92 inhibition were similar to those obtained through specific 
ERK5-silencing techniques, new chemical inhibitors should be generated to avoid 
possible unspecific effects related to bromodomain inhibition.  
A second generation of ERK5 kinase activity inhibitors was obtained 
synthetizing derivatives of the benzopyrimidodiazepinone XMD8-92, showing a potent 
inhibition of ERK5 with IC50 values ranging from 8 to 190 nM. Preliminary data about 
the application of these new molecules show that the inhibition of ERK5 had no 
antiproliferative and anti-inflammatory activity (Lin et al., 2016). TG02, an oral 
pyrimidine-based multi-kinase inhibitor, blocks CDKs 1, 2, 3, 5, and 9 with IC50 values 
below 10 nM in addition to janus kinase 2 (JAK2), p38d and ERK5 with IC50 values of 
19, 56, and 43 nM, respectively. This novel anti-cancer agent inhibited proliferation and 
survival of multiple myeloma cell linesalso as single agents and has recently completed 
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phase I of clinical trials for treatment of leukemia and multiple myeloma patients 
(Álvarez-Fernández et al., 2013). Recently, TG02 has been proposed also in 
combination with chemotherapy against triple negative breast cancer (Miranda et al., 
2015). JWG0-45, another novel ERK5 inhibitor, shows similar biological effects 
compared to XMD8-92 and much lower affinity toward BRD proteins (William et al., 
2016).  
Reactivation of ERK5 is involved in drug resistance to cytotoxic agents or target 
therapy. For this reason the ERK5 inhibitors are proposed in combination therapies. In 
colorectal cancer the clinical efficacy of the pyrimidine analog 5-fluorouracil (5-FU) is 
reduced by the development of resistance. Treatment of colon cancer cells HCT116 and 
SW620 with 5-FU reduced the MEK5 and ERK5 activation. Constitutive activation of 
MEK5 conferred a survival advantage to HCT116 cells exposed to 5-FU compared to 
control cells, whereas downregulation of MEK5 signaling with the ERK5 inhibitor 
XMD8-92, enhanced sensitivity of HCT116 cells to 5-FU-induced cytotoxicity through 
stimulation of p53-dependent transcriptional activation of p21 and Puma. In vivo, 
combination therapy using 5-FU and XMD8-92 significantly increased apoptosis and 
reduced tumor burden compared to monotherapy of each compound (Pereira et al., 
2016). Consistent with this study, in both HeLa cervical cancer cells and A549 lung 
cancer cells the combined treatment with XMD8-92 and the chemotherapeutic agent 
doxorubicin demonstrated a synergistic induction of p53 and significantly promoted 
tumor regression (Hoang et al., 2017). Recently a compensatory mechanism between 
the ERK1/2 and ERK5 pathways has been described in colorectal cancer (CRC), with 
important implication for cancer therapy. According to this model, Ras is constitutively 
active in CRC and preferentially activates the Raf–MEK1/2–ERK1/2 module. 
Importantly, ERK1/2 activation also results in the activation of negative feedback 
mechanisms that suppress its upstream kinases and activate dual specificity 
phosphatases (DUSPs), which turn off ERK5 kinase activity. Upon MEK1/2 inhibition 
or genetic knockout of ERK1/2, the lack of negative feedback mechanisms results in 
upregulation of the Ras–Raf–MEK5–ERK5 module, which maintains cell proliferation 
under physiological conditions, or supports uncontrolled cell proliferation in colorectal 
cancer, respectively. Compensatory upregulation of the ERK5 pathway in CRC can be 
reversed by targeted treatment with its specific inhibitor, XMD8-92, and paves the way 
for the application of a combined therapy to block ERK5 reactivation (de Jong et al., 





Figure 1.13 Compensatory mechanisms between ERK1/2 and ERK5 pathways in intestinal epithelial 
cells (a) and colon cancer (b) (de Jong et al., 2016). 
 
Taken together, these results confirm the important role of ERK5 in cancer. The 
tight correlation between ERK5 and other pathways important in melanoma, such as 





1.3 The Hedgehog pathway 
Initially discovered in Drosophila melanogaster, the Hedgehog (HH) pathway is a 
highly conserved signaling in almost all animal kingdoms. It plays a crucial role in 
embryonic development, particularly during organogenesis in the regulation of cell 
proliferation, differentiation and tissue patterning. Indeed, HH pathway inactivation 
causes defects in the development process, while its hyperactivation has been described 
in various forms of solid and hematologic malignancies. This pathway is also active in 
the adult, where it is involved in tissues homeostasis, repair and regeneration, and in 
maintenance of the stem cell pool (Varjosalo et al., 2008). 
In mammals, the canonical activation of HH pathway is promoted by three 
ligands: Sonic hedgehog (SHH), Desert hedgehog (DHH) and Indian hedgehog (IHH). 
HH ligands are proteins associated with the membrane, synthesized as inactive 
precursors that meet a number of post-translational modifications before being secreted 
from the cell in an active form. Despite their high homology, the three HH ligands have 
different function and localization (Jiang et al., 2008). Sonic HH is the most expressed 
in mammals and is crucial for the formation of many systems, including limbs, middle 
brain structures, lumbar spine, thalamus and teeth. It is also involved in the 
development of many endothelial tissues during organogenesis (Varjosalo et al., 2008). 
The main actors of the HH pathway are two transmembrane receptors: the 12-pass 
transmembrane protein receptor Patched (PTCH), which resides at the basis of primary 
cilium and regulates the activity of Smoothened (SMO), a 7-domain transmembrane 
receptor coupled to G protein. The mechanism of SMO regulation byPTCH is not yet 
fully clarified, but presumably involves primary cilia, which play an important role in 
transmitting this signal. Cilia are projections of the cell membrane present on most 
vertebrate cells and involved in the detection of chemical and mechanical signals, 
functioning as a control center for differentiation signals and polarization (Robbins et 
al., 2012). SMO proteins can exist in three different states: an inactive internalized form 
(SMOA), which is in balance with an inactive form (SMOB), linked to the cilium. The 
third activated form (SMOC) is generated from SMOB following phosphorylation in a 
region rich in arginine; this phosphorylation allows SMO to move into the cilia. In 
absence of the ligand, PTCH inhibits the conversion of SMO into active form, 
maintaining the pathway inactive. Binding of HH ligand to PTCH allows to the 
receptor/ligand complex to be dislocated outside the primary cilium and to be 
internalized into endosomic vesicles, thus losing its ability to inhibit SMO. SMO is 
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converted in the active form and can move into the tips of the cilium, activating a 
cascade of intracellular events. The ligand interaction with PTCH is regulated by 
several proteins: HH-interacting protein (Hip) competes with PTCH for HH binding and 
acts as a negative regulator of the pathway. The positive regulators, acting as HH co-
receptor, includes Cdo, Boc, Gas1 and Glypican-3 (Heretsch et al., 2010). Following the 
activation of the HH pathway, SMO promotes the activation of transcription factors 
GLI, the final effectors of the pathway at the nuclear level. 
 
 
Figure 1.14. The Hedgehog signaling pathway in the primary cilia (Heretsch et al., 2010). 
 
1.3.1 The GLI transcription factors and their regulation 
The final mediators of HH pathway belong to the family of Kruppel transcriptional 
factors. In the eukaryotes, three transcription factors involved in the HH pathway were 
identified: GLI1, GLI2 and GLI3. GLI proteins are characterized by the presence of five 
conserved C2-H2 zinc-finger DNA binding domains and a histidine/cysteine linker 
sequence. The activation of HH signaling promotes the binding to the consensus 
sequence (5'-TGGGTGGTC-3') on the promoter of target genes, mediating a number of 
cellular responses (Kinzler et al., 1990). 
GLI1 is considered the direct target of HH signaling pathway, while GLI2 and 
GLI3 act as transcriptional regulators in the late phase. GLI1 acts as a strong 
transcriptional activator of target genes and is regulated primarily at the transcriptional 
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level directly by the HH pathway, being a transcriptional target of GLI2 and GLI3 
(Kasper et al., 2006). Alternative splicing of the full length (FL) form of GLI1 generates 
two other possible isoforms: GLI1 deltaN (N-terminal deletion variant) and tGLI1 
(truncated GLI1), which differ in function and expression profile. GLI1FL and GLI1 
deltaN are expressed both in normal and tumor tissues, whereas tGLI1 is expressed 
exclusively in tumor cells. tGLI1 is a more powerful transcriptional factor than the 
GLI1FL form and is highly expressed in various types of cancer, particularly in 
glioblastoma (GBM), where it is associated with an increase in motility and 
invasiveness, and in breast cancer (Carpenter et al., 2012). In eukaryotes, the activity of 
the three transcription factors GLI is context dependent and is differentially regulated 
by several factors, influencing cellular localization (nuclear or cytoplasmic) and post-
translational modifications (phosphorylation, ubiquitination, acetylation and proteolytic 
degradation) of these proteins. While GLI1 acts exclusively as an activator, GLI2 and 
GLI3 display both positive and negative transcriptional functions. Modifications 
occurring at the N-terminal domain of GLI2 and GLI3 are responsible for the function 
of the two transcription factors. GLI2 has an N-terminal repressive domain and aC-
terminal activation domain. It can then act as an activator oras a transcriptional 
repressor in the C-terminal truncated form (Ruiz i Altaba, 1999). GLI3, on the other 
hand, can only act as a repressor in its C-terminal truncated form. It has been shown that 
although GLI1 is predominantly regulated transcriptionally from the HH pathway, 
binding of GLI2 and GLI3 to the promoter is required for its transcription (Kasper et al., 
2006). The subcellular localization of GLI1 is tightly controlled. HH stimulation 
induces the GLI1 nuclear localization, correlating with high transcriptional activity. In 
absence of HH pathway activation, GLI1 is retained in the cytoplasm and degraded by 
the proteasome. SUFU, one of the main negative regulators of HH signalling, interacts 
with GLI1 both at the N-terminal (amino acids 116–125) and at the C-terminal region 
and inhibits GLI1 both by retaining it in the cytoplasm and by repressing its 
transcriptional activity in the nucleus (Merchant et al., 2004). NUMB kinase can also 
act on GLI1, creating a recognition site for the E3 ubiquitin ligase ITCH, promoting its 
degradation (Di Marcotullio et al., 2006). In the absence of HH, also GLI2 and GLI3 
ligands complex with SUFU protein. They are sequentially phosphorylated by different 
kinases: PKA (protein kinase A), GSK3β (glycogen synthase kinase 3β) and CK1 
(casein kinase1). This modification creates a F-box recognition site for β-TrCP, an E3 
ubiquitin ligase that recognizes GLI2/GLI3 and induces a proteasome-dependent 
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degradation. This proteolysis generates repressive conformations that prevent the 
expression of target genes. PKA is another important negative regulator of HH pathway: 
it phosphorylates GLI1 on residue Thr374, hiding the sequence for nuclear localization. 
PKA also phosphorylates GLI2 and GLI3 in the C-terminal region, thus favoring 
subsequent phosphorylation by CK1 and GSK3β and the βTrCP dependent protease 
degradation (Heretsch et al., 2010). The dual specificity Yak-1 related kinases 1 
(DYRK1) and 2 (DYRK2) modulate HH pathway in opposite ways. DYRK1 
phosphorylates GLI1 in its N- and C-terminal regions, increasing its nuclear retention 
and transcriptional activity, whereas DYRK2 reduces Gli1 transcriptional activity. 
Dyrk2 kinase directly phosphorylate GLI2, causing its degradation, and promotes the 
repressive form of GLI3. The acetylation of GLI1 and GLI2 seems to have an inhibitory 
effect on their transcriptional activity; this inhibition is removed from the HDAC 
activity, which promotes the activation of these transcriptional factors and promotes cell 
proliferation. Among the positive regulators of the HH pathway, the kinase ULK3 
phosphorylates the GLI proteins by increasing their activation. STK36 is a Ser/Thr 
kinase that antagonizes SuFU inhibitory activity, contributing to the activation of the 
pathway. Missing in Metastasis (MIM) protein is encoded by a HH-responsive gene and 
is part of the Gli/SuFu complex, which acts by enhancing the transcriptional activity of 
GLI1 and GLI2 (Choudhry et al., 2014). The activation of the MEK1/ribosomal S6 
kinase 2 (RSK2) cascade stabilizes GLI2 protein. RSK2 phosphorylates GSK3β, 
reducing its activity on GLI2 and its resulting ubiquitination and processing. This 





Figure 1.15 Key components of the HH signaling pathway (Pandolfi et al., 2015). 
 
The GLI transcription factors regulate the expression of a number of targets 
involved in proliferation and differentiation (Cyclin D1 and D2, E2F1, N-Myc, 
FOXM1, PDGFRα, IGFBP3 and IGFBP6, Hes1, Neogenin), cell survival (BCL-2), self-
renewal (Bmi1, Nanog, Sox2), angiogenesis (Vegf, Cyr61), cardiomyogenesis 
(MEF2C), epithelial–mesenchymal transition (Snail1, Sip1, Elk1 and Msx2) and 
invasiveness (Osteopontin). Interestingly, GLI transcription factors control the 
expression of some genes belonging to the HH pathway itself, including PTCH, HIP, 
Gas1, and GLI1, thus creating a negative feedback control system (through induction of 
PTCH and HIP) and a positive one (through the activation of GLI1 and Gas1 down-
regulation) within the HH signaling pathway itself (Choudhry et al., 2014). 
 
1.3.2 The Hedgehog signaling in cancer 
Abnormal activation of the HH-GLI pathway is associated with a variety of tumors, 
including those of the skin, brain, lungs, prostate, breast, gastrointestinal tract and 
blood. The constitutive activation of the HH pathway promotes tumorigenesis through 
various processes. HH pathway promotes tumor cell proliferation and survival, inducing 
cell cycle regulators such as cyclin D1, cyclin D2, cyclin B1, p21, Bmi1, telomerase 
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activity and through the regulation of apoptosis genes (Marini et al., 2011). The HH 
pathway deregulation sustains an aggressive and metastatic tumor phenotype. Indeed, 
genes involved in EMT, motility and cell adhesion (Snail, E-cadherin, Osteopontin) are 
under the control of GLI transcription factors. Moreover, this pathway promotes 
invasiveness through the regulation of extracellular matrix metalloproteases (MMPs). 
Hedgehog also seems to favor the neo-angiogenesis process by transducing the VEGF 
signal, which is deregulated in most tumors (Brechbiel et al., 2014). 
Multiple mechanisms of HH pathway canonical activation have been described 
in cancer (Scales et al., 2009). The constitutive HH pathway activation may occur in 
aligand-independent manner, mediated by loss of function mutations in the negative 
regulators (PTCH1, SUFU), activating mutations in SMO, or gene amplifications of 
GLI1and GLI2. This activation mechanism occurs more often in basal cell carcinoma 
(BCC), medulloblastoma, rhabdomyosarcoma and Gorlin syndrome. In many tumors, 
the activation of the HH pathway occurs in a ligand dependent manner, through 
autocrine or paracrine signaling. This mechanism has been identified in several types of 
cancer, including lung, pancreas, gastrointestinal tract, prostate and colon cancer, 
glioma and melanoma. Tumor cells are able to secrete and respond to HH ligands and 
show increased HH ligands expression apparently in absence of genetic alterations of 
HH pathway components. In the ligand dependent paracrine activation of HH pathway, 
HH ligands secreted by cancer cells activate HH signaling in the surrounding stroma, as 
happens physiologically during development. The mechanisms by which the HH 
signaling and the tumor stroma interact during paracrine signaling are not completely 
understood. Evidence supporting this mechanism derives from studies in human tumor 
xenograft models of pancreatic and colorectal cancers. Similarly, in the reverse 
paracrine HH pathway activation, HH ligands are secreted by the tumor 
microenvironment and activate the pathway in tumor cells. This mechanism is observed 
in an experimental model of glioma and in hematological malignancies, such as B-cell 
lymphoma and mantle cell lymphoma (Scales et al., 2009; Robbins et al., 2012). The 
HH signaling has also been implicated in the regulation of cancer stem cells (CSC), 
confirming its critical role in cancer. Activated HH signaling has been identified in 
CSCs of many solid tumors, such as glioblastoma, breast, colon, pancreatic cancer, 
melanoma, and hematological malignancies, including CML and multiple myeloma. 
HH activation increases tumor initiating populations and contribute to self-renewal, 





Figure 1.16 Modes of activation of the HH pathway in cancer (Scales et al., 2009). 
 
The activity of HH-GLI pathway in human cancer is the result of its functional 
cooperation with other signaling pathway and of the direct or indirect regulation on the 
final effectors of the HH pathway. Several studies suggest that GLI proteins may be 
regulated by different proliferative and oncogenic inputs, in addition or independently 
of the canonical HH signaling (Pandolfi et al., 2015). In cancer the acquisition of 
oncogenic mutations and the inactivation of oncosoppressors alter this balance, leading 
to a constitutive activation of the pathway (Aberger et al., 2014). 
 
1.3.3 Modulation of HH-GLI signaling by oncogenic pathways 
Evidences of a non-canonical activation of HH-GLI signaling by other oncogenic 
pathways, such as RAS/RAF/MEK, PI3K/AKT/mTOR, Notch, TGFβ, Wnt/βcatenin, 
have been reported in many types of cancer. AKT signaling pathway promotes nuclear 
translocation and transcriptional activation of GLI1 in melanoma. The PI3K/AKT 
pathway inhibits PKA phosphorylation on GLI2, preventing GLI2 degradation and thus 
increasing GLI2-dependent transcription. PTEN, a negative regulator of PI3K/AKT 
pathway, is frequently mutated in several tumors and inhibits GLI1 transcriptional 
activity in glioblastoma. The mTOR/S6K1 pathway, activated by TNF-α, promotes 
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GLI1 transcriptional activity. S6K1 phosphorylates GLI1 and induce the release by its 
SUFU inhibitor. TGF-β also promotes the activation of HH pathway by increasing the 
expression of GLI2 through Smad3 and Smad4, resulting in further increase in GLI1 
expression (Brechbiel et al., 2014). It has been identified the existence of a regulatory 
loop in which p53 and GLI1 negatively control each other. p53 reduces GLI1 activity, 
nuclear localization and protein levels. The HH pathway inhibits p53 promoting MDM2 
activating phosphorylation on Ser166 and Ser186 residues, thus favoring p53 
degradation (Stecca et al., 2009). A positive reciprocal loop links NANOG and HH 
pathway. Notch inhibits the HH signaling pathway through Hes1, a transcription factor 
that binds GLI1 to the level of the first intron and inhibits its expression. Activation of 
WNT/β-catenin signaling induces HH-GLI pathway increasing GLI1 expression. In 
Ewing's sarcoma, the oncogenic activation of GLI1 is directly promoted by the 
EWS/FLI transcription factor, which results from the translocation between 
chromosomes 11 and 22 that characterizes this tumor (Pandolfi et al., 2015). Tyrosine 
kinase receptors of several growth factors, including EGF (epidermal growth factor), 
PDGF (platelet-derived growth factor), and FGF (fibroblast growth factor) are 
important GLI positive modulators. It has been shown that HH and these growth factors 
promote synergistically cell transformation by integrating their signaling at different 
levels. Furthermore, HH is able to activate the tyrosine kinase receptor, particularly in 
the case of EGFR. This activation promotes intracellular activation of proliferative 
pathways of PI3K/AKT and RAF/MEK/MAPK (Aberger et al., 2014). Interplay 
between HH pathway and RAS/RAF/MEK has also been described in normal cells and 





Figure 1.17 Integration of multiple signaling inputs from different pathways converging on HH-GLI 
pathway (Aberger et al., 2014). 
 
1.3.4 Crosstalk between HH-GLI and MAPK pathway in melanoma 
Several studies demonstrate the existence of a crosstalk between HH signaling and 
MAPK pathway, especially with the MEK1/2-ERK1/2 pathway. Both signaling 
pathways are crucial in different biological functions and are deregulated in several 
types of cancers, first of all in melanoma. Constitutively activated ERK1/2 is found in 
the majority of melanoma, due to the mutually exclusive activating mutations in BRAF 
(present in 50% of melanomas) and NRAS (found in 15–20% of melanomas). Recent 
studies indicate that the HH-GLI signaling is active in melanoma and supports growth 
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and proliferation of human melanoma cells, in vitro and in vivo. Indeed, SMO 
antagonists Cyclopamine or Sonidegib treatment reduces proliferation of human 
melanoma cells and decreases human melanoma xenograft growth in nude mice (Stecca 
et al., 2007; O’Reilly et al., 2013; Jalili et al., 2013). Interestingly, BRAF mutant cell 
lines are more sensitive to Sonidegib than BRAF wild type melanoma cells, indicating 
that the combined inhibition of BRAF (Vemurafenib) and Hedgehog (Sonidegib) can 
synergistically reduce melanoma cell proliferation (O’Reilly KE et al., 2013). MEK1/2-
ERK1/2 signaling acts upstream of HH pathway, regulating the activity of the GLI 
transcription factors. Oncogenic NRAS (NRASQ61K) and HRAS (HRASV12G) 
modulate SUFU inhibitory activity and enhance GLI1 function, increasing its 
transcriptional activity and nuclear localization (Stecca et al., 2007). TGF-β signaling 
regulates melanoma tumorigenesis and metastasis and is a major inducer of EMT. GLI2 
has been identified as a direct transcriptional target of the TGF-β/SMAD pathway in 
melanoma cells. High GLI2 expression is associated with a more aggressive phenotype, 
characterized by loss of the cell-cell adhesion molecule E-cadherin, hallmark of cancer 
progression (Javelaud et al., 2011). Activation of ERK 1/2 promotes cell proliferation 
and induces expression of SHH, thus activating the HH pathway in a ligand dependent 
manner. Recent studies have shown that treatment with BRAF inhibitors (BRAFi) 
induces HH-GLI pathway activation, which is responsible for PDGFR up-regulation 
following Vemurafenib treatment in human melanoma cells. PDGFR up regulation is 
one of the resistance mechanisms described in metastatic melanoma following BRAFi 
treatment (Sabbatino et al., 2014). Therefore, also the HH pathway may activate 
ERK1/2 by several mechanisms not entirely characterized. The expression of GLI-
dependent target genes, such as PDGFR and IRS1, activates downstream ERK1/2 in a 
GLI-independent manner. Moreover, transactivation of EGFR by SHH has also been 




Figure 1.18 Activation of HH signaling by the RAS-RAF-MEK-ERK1/2 pathway (Rovida et al., 2015). 
 
The HH pathway may interact non only with ERK1/2, but also with other final 
MAPK effectors such as JNK and p38 (Rovida et al., 2015). To date no interplay has 
been described between ERK5 and HH pathway. However, a report demonstrates that 
GLI2 and MEF2c, an ERK5 target, activate each other expression. During 
cardiomyogenesis MEF2c binds to GLI2 promoter, activating its expression (Voronova 
et al., 2012). The similarity between MEK-ERK1/2 pathway and ERK5 promped us to 
speculate about an interaction between ERK5 and the HH pathway. 
 
1.3.5 Inhibitors of HH-GLI pathway 
Given the important roles played during tumorigenesis, the HH pathway has been a key 
target for cancer therapy. Many inhibitors currently available can interfere with this 
pathway by exploiting mainly three strategies: 
• inhibition of HH ligand activity; 
• inhibition of SMO translocation and activation; 





Figure 1.19 HH pathway inhibitors. Inhibitors are classified according to level of the pathway inhibited: 
SMO translocation and activation (blue), HH/PTCH interaction (orange) and GLI nuclear translocation 
and transcriptional activity (red) (Pandolfi et al., 2015). 
 
HH ligands inhibition is a poorly used strategy in therapy and is based on the 
interference between HH ligands and PTCH. Small molecules, such as Robotnikinin, or 
Sonic HH specific monoclonal antibodies, such as 5E1, attenuate the growth of cancer 
cells in some tumors, including lung cancer (Stanton et al., 2009). Inhibition of SMO is 
the most used strategy to target HH pathway. Cyclopamine, an alkaloid extracted from 
Veratum Album, is the natural ligand of SMO extensively used to study HH pathway. Its 
application as therapeutic agent is hindered by its unfavorable pharmacokinetic 
properties (poor oral solubility, chemical instability). All SMO inhibitors currently used 
in clinical trials are semi-synthetic or synthetic cyclopamine derivatives, including the 
most soluble cyclopamine analogues (IPI-926), KAAD-cyclopamine, agents that inhibit 
the conversion of SMO into active form (SANT 74-75), agents that inhibit the 
translocation of the active form of SMO through cilia (SANT 1-4) (Lin et al., 2012). 
Additional SMO inhibitors with a structure different from Cyclopamine are currently 
available and many, including Vismodegib (GDC-0449), Sonidegib (LDE-225), BMS-
833923, PF-04449913 and LY2940680 are being investigated in clinical trials in a 
number of advanced cancers. Among these, Vismodegib (GDC-0499, 
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Genentech/Roche/Curis), is the first Hedgehog signalling antagonist approved by U.S. 
Food and Drug Administration (FDA) for treatment of advanced or metastatic basal cell 
carcinoma (BCC). Despite the excellent results reported in clinical trials, in particular 
for Vismodegib (GDC-0449) and Sonedegib (LDE225), their anticancer activity seems 
to be limited by the acquisition of resistance due to different mechanisms. The most 
relevant are the acquisition of mutations in human SMO (D473H); amplification of 
downstream HH target genes (GLI2 and CyclinD1); increased drug efflux through the 
adenosine triphosphate (ATP)-binding cassette transporter (ABC); upregulation of other 
oncogenic signalling, such as PI3K/AKT pathway observed during LDE-225 treatment, 
leading to a non-canonical activation of the pathway (Pandolfi et al., 2015). Targeting 
the final effectors of the HH signalling with GLI inhibitors would provide a good 
approach to block both canonical and non-canonical HH pathway activation and 
perhaps overcome anti SMO drug resistance. Unfortunately, to date only few molecules 
acting on GLI proteins have been identified (GANT61 and GANT58, HPI-1, HPI-2) 
and their use is only limited to preclinical studies. The only GLI inhibitors used in 
therapy are the arsenic trioxide (ATO), approved by FDA for acute promyelocytic 
leukaemia, and pyrvinium, an anti-pinworm agent (Onishi et al., 2011). Recently, the 
identification of the Gli1 zinc fingers involved in DNA binding allowes to synthesize a 
small molecule (Glabrescione B) that interferes with the interaction of GLI with DNA. 
Through the strong inhibition of Gli1 activity, Glabrescione B inhibits growth of HH-
dependent BCC and MB tumour cells in vitro and in vivo as well as self-renewal ability 
and clonogenicity of CSCs (Infante et al., 2015).  
Based on crosstalk between HH and other pathways, clinical trials and 
experimental studies have been initiated to evaluate the therapeutic efficacy of the 
association between SMO or GLI inhibitors and inhibitors of EGFR and MEK, the most 
interesting regulator of HH pathway. The combination treatment with Cyclopamine and 
Gefitinib (EGFR inhibitor) has led to a reduction in tumor growth and an increase in 
apoptosis in pancreatic cancer. Also in the neck head tumors (HNSCC) the association 
between the SMO inhibitor Saridegib (IPI-926) and Cetuximab has given excellent 
results, allowing to inhibit tumor cell proliferation and increase the duration of response 
(Ruch et al., 2013). In glioblastoma, combined therapy between Cyclopamine and 
Erlotinib (EGFR inhibitor) improved the effectiveness of therapy, reducing the risk of 
recurrence of the tumor by Cyclopamine administration in a first phase, followed by the 
association with Erlotinib in a second phase of treatment. This demonstrates that HH 
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stimulation by EGFR is required for the development of the tumor. In lung cancer 
(NSCLC) xenograft pretreatment with Vismodegib (SMO inhibitor), Cisplatin and 
Erlotinib increases the antitumor activity compared with monotherapy. Lastly, in 
prostate cancer, combined treatment with SMO inhibitors (SANT1) and MEK inhibitors 
(PD325901 and U0126) shows greater antiproliferative activity than conventional MEK 
inhibitors (Brechbiel et al., 2014). 
The promising results obtained in clinical trials highlight the importance to study 
the interplay between different pathways, in order to identify new pharmacological 




2. AIM OF THE STUDY 
Malignant melanoma is among the most aggressive cancers and its incidence is 
increasing worldwide. While early stage melanoma can be cured with surgery, 
prognosis of metastatic melanoma is still poor. In the last few years targeted therapy and 
immunotherapy have improved survival of patients with metastatic melanoma, however 
available treatments are still unsatisfactory, showing an urgent need to identify new 
therapeutic targets. The BRAF-MEK1/2-ERK1/2 pathway is active in the majority of 
melanoma and its role has been extensively studied in human as well as in mouse 
models of melanoma. Another signaling pathway that is required for melanoma cell 
growth in vitro and in vivo is the Hedgehog signaling (Stecca et al., 2007; O’Reilly et 
al., 2013; Jalili et al., 2013). An emerging member of the MAPK family of most recent 
discovery is the kinase ERK5, which is involved in the regulation of cell survival, anti-
apoptotic signaling, angiogenesis, differentiation and proliferation. ERK5 plays a role in 
the pathogenesis of different types of cancer, including highly aggressive forms of 
breast and prostate cancers, hepatocellular carcinoma and multiple myeloma (Al-Ejeh et 
al., 2014; Carvajal-Vergara et al., 2005; Rovida et al., 2015; Yang et al., 2011; Simões 
et al., 2016). A recent report suggested an association of ERK5 with drug resistance to 
combined inhibition of BRAF and MEK1/2 in melanoma (Song et al., 2017). 
The aim of this study is to explore the role of ERK5 in melanoma and its 
interplay with oncogenic BRAF and the Hedgehog signaling, with the ultimate 
objective to identify novel therapeutic options for metastatic melanoma. In particular, 
we propose the following specific aims: 
1. To investigate the role of ERK5 in the proliferation of melanoma cells in vitro 
and in vivo, by genetic silencing of ERK5 with specific short hairpin RNAs and by 
pharmacological inhibition of the MEK5-ERK5 pathway with small molecules.  
2. To investigate whether oncogenic BRAF regulates ERK5, since BRAF is 
mutated in more than half of human melanoma cases. The identification of an interplay 
between these two kinases may open the possibility to target both pathways as a 
strategy to inhibit melanoma cell proliferation. 
3. To investigate the interplay between ERK5 and the Hedgehog pathway, a 
signaling that our group first showed critical for growth, recurrence and metastasis of 
melanoma xenografts in mice. In particular, we will test whether ERK5 affects the 




3. MATERIALS AND METHODS 
 
3.1 Cell culture and melanoma patients samples 
A375 (CRL-1619), MeWo (HTB-65), Human Embryonic Kidney 293 (HEK-293T) 
(CRL-3216) and embryonic fibroblast NIH3T3 (CRL-1658) cell lines were obtained 
from ATCC (Manassas, VA, www.lgcstandards-atcc.org). SK-Mel-2, SK-Mel-5, SK-
Mel-28 and 501-Mel melanoma cell lines were kindly provided by Dr. Laura Poliseno 
(CRL-ITT, Pisa, Italy). Patient-derived SSM2c and M26c melanoma cells were 
obtained after protocols approved by the Ethics Committee (Santini et al., 2012; 
Pandolfi et al., 2013) from patients of the Plastic Surgery Unit of the S.M. Annunziata 
Hospital (Florence, Italy) and Dermatology Department and Medical-Surgical Critical 
Area of the University of Florence (Florence, Italy). After mechanical disruption, 
tumors were incubated for 1 hour at 37°C with 1mg/ml collagenase A and 20µg/ml 
DNase I (Roche Applied Science, Basel, Switzerland) in DMEM/F12 (Euroclone, 
Milan, Italy), in order to eliminate residual fat tissue and cellular structures. After 
dissociation and filtration in 70 µm cell strainers, cells were grown in DMEM/F12 with 
10% fetal bovine serum (FBS- Carlo Erba) and epidermal growth factor (EGF) (5ng/ml) 
(Invitrogen, Carlsbad, CA). SSM2c and M26c cultures were cloned from the original 
metastases (SSM2 and M26, respectively) by plating one cell per well. Patient-derived 
melanomas were passaged one to two times prior to RNA extraction and in vitro 
experiments. The identity of melanoma cells was verified by immunocytochemistry 
using primary antibodies specific for melanoma: anti-Melan A (A103), anti-S100 
(Dako, Glostrup, DK) and anti-Vimentin (V9) (Santa Cruz Biotechnology).  
All cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
(Euroclone, Milan, Italy, http://www.euroclonegroup.it) supplemented with 10% fetal 
bovine serum (FBS- Carlo Erba), 1% Penicillin-streptomycin, 1% L-Glutamine (Lonza, 
Basel, Switzerland). Cell lines were authenticated by cell profiling (Promega PowerPlex 
Fusion System kit; BMR Genomics s.r.l; Padova, Italy) once a year. Mycoplasma was 
periodically tested by 4’,6-diamidino-2-phenylindole (DAPI) inspection and PCR upon 
thawing of a new batch of cells, once a month. Cultures are renewed every two months. 




Cell line Mutations 
A375 BRAF V600E 
SK-Mel-2 NRAS Q61R 
SK-Mel-5 BRAF V600E 
SK-Mel-28 BRAF V600E 
501-Mel BRAF V600E 
MeWo NF1, p53, CDKN2A trunc/indel 
M26c wt BRAF/ wt NRAS 
SSM2c wt BRAF / wt NRAS 
Table 3.1 Genetic alterations of melanoma cell lines used in this work. 
 
3.2 Drugs 
Considering that ERK5 was positively regulated by serum and growth factors, before 
treatment cells were starved for 24 hours and pharmacological treatment was performed 
in low serum condition. The following drugs were used: ERK5 inhibitors XMD8-92 
(Yang et al., 2010) and JWG-045 (Williams et al., 2016) have been developed in Gray’s 
laboratory; MEK5 inhibitor BIX02189 (Tatake et al., 2008), ERK1/2 inhibitor 
SCH772984 (Morris et al., 2013) and BRAF-V600E inhibitor Vemurafenib 
(Selleckchem, Italy, www.selleckchem.com) (Sala et al., 2008); CDK1 inhibitor RO-
3306 (MedChem Express, www.medchemexpress.com) (Vassilev et al., 2006). For the 
selection of transduced cells we used puromycin (2µg/ml). Finally, we used SAG 
(100nM for 48hrs, Enzo Life Sciences, Farmingdale, NY, USA) as agonist of SMO 
receptor. 
 
3.3 Plasmids and transfections 
pcDNA3.1-BRAF-V600E and pcDNA3.1-BRAFwt constructs were a kind gift from 
Laura Poliseno (CRL-ITT, Pisa, Italy). pcDNA3.1-HA-ERK5wt construct was a kind 
gift from Atanasio Pandiella (CIC, Salamanca, Spain). The pcMV5-MEK5DD-HA (a 
constitutively active form of MEK5) was generously provided by Jiing-Dwan Lee 
(Scripps Institute, La Jolla, CA, USA). HEK-293T or M26c cells were plated in 60 mm 
diameter dishes (3x105 cells/dish) and transfected after 24 hours with a total amount of 
3µg of plasmid DNA. Transfection was performed in the reduced serum media 
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OptiMEM (Life Technologies, Carlsbad, CA, USA) using Polyethylenimine (jetPEI 
reagent, Polypus Transfection, Euroclone, Milan, Italy) or X-tremeGENE (Roche 
Applied Science) as transfection reagent. Both transfection agents are added to the 
diluted DNA in a ratio of 3:1. Cells were lysed after 48 hours. When provided, drugs 
were added 18 hours before lysis. 
 
3.4 Lentiviral vectors, virus production and transductions 
Lentiviral vectors for stable knockdown of ERK5 in melanoma cells were TRC1.5-
pLKO.1-puro vector containing non targeting sequence shRNA (LV-c), targeting 
human MAPK7 (NM_139032, NM_139034, NM_002749, NM_139033) clone ID: 
TRCN0000010275 (LV-shERK5-275) and clone ID:TRCN0000010262(LV-shERK5-
262). 
HEK293T cells were seeded in 100 mm diameter dishes (2×106 cells/dish) in 
DMEM supplemented with 10% FBS and 2 mM glutamine without antibiotics 
(complete medium). After 24 hours (40%–70% confluency) medium was replaced with 
fresh complete medium. The plasmid mixture was prepared as follows: 8 µg of lentiviral 
vectors encoding for shRNA, 4 µg of pRSV-Rev, 4 µg pMDLg/pRRE and 4 µg 
pMDG.1-VSV and 150 mM NaCl (Polypus Transfection, Euroclone, Milan, Italy) to a 
final volume of 250 µL. Transfection was performed using 40 µL of jetPEI reagent 
(Polypus Transfection, Euroclone, Milan, Italy) following the manufacturer’s protocol. 
Twenty-four hours after transfection, the medium was replaced with fresh complete 
medium. The following day culture media from HEK293T was collected and fresh 
complete medium added to the cells. Harvested medium was centrifuged at 1500 rpm 
for 5 min and filtered through a 0.45 µm filter and either directly added to melanoma 
cells or stored at −80°C for later use. This procedure was repeated 1 day after. For 
infection, melanoma cells were seeded in a 60 mm diameter dish (3×105 cells/dish). At 
an optimal confluence of 50%, 2 mL/dish of virus supernatant were added in the 
presence of 5 µg/mL polybrene. Infected cells were selected with 2 µg/mL puromycin 








3.5 Measurement of cell viability and cell cycle phase distribution analysis 
The number of viable cells in culture was evaluated by counting trypan blue-negative 
cells at the indicated time-points with a hemocytometer (Burker counting chamber). For 
growth curve with MEK5/ERK5 inhibitors we seeded cells in 12-well plates in low 
serum condition (DMEM 2.5% FBS, 1% Penicillin-streptomycin, 1% L-Glutamine). 
We seeded 18000 cells/well for M26c and SSM2c cell lines and 12000 cell/well for 
A375, SK-Mel-5 and 501-Mel cell lines. Viable cells were counted after 72 hours of 
treatment. IC50 values were calculated using GraphPad Prism software.  
For cell cycle phase distribution analysis, we seeded 150000 cells in 60 mm 
diameter dishes with DMEM 0.5% FBS, 1% Penicillin-streptomycin, 1% L-Glutamine. 
Cells were harvested after 48 hours and resuspended in 400 µl of an hypotonic solution 
containing 50 µg/mL propidium iodide, 0.1% w/v trisodium citrate and 0.1% NP40. 
Cytometric analysis was performed with FACS Canto II (Beckton & Dickinson, San 
Josè, CA, USA) and analyzed using ModFit LT software (Verity Software House, 
Topsham, ME). 
 
3.6 Cell lysis, Western blotting and immunoprecipitation 
Cells were lysed with different buffers, according to the protein to detect. For GLIs 
detection, cells were harvested, centrifuged at 1500 rpm and pellet was resuspended in 
RIPA buffer (1% NP-40, 150mM NaCl, 5mM EDTA, 0.25% NaDOC, 50mM Tris-HCl 
pH 7.5, 1% SDS) added with 1X Complete EDTA-free Protease Inhibitor Cocktail 
(Roche Applied Science) and phosphatase inhibitors. After incubation in ice for 20 
minutes, lysate was centrifuged for 20 minutes at 14000 rpm. The supernatant 
containing the whole cell extract (WCE) was recovered and quantified with Coomassie 
Protein Assay Kit (Thermo Scientific, Rockford, IL, USA). For Western Blot 80µg of 
proteins were resolved on a sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred onto a nitrocellulose membrane (Bio-Rad, 
Hercules, CA, USA). Membranes were blocked in 6% non-fat dry milk (Bio-Rad) 
diluted in PBS-Tween buffer (PBS and 0.05% Tween 20, PBS-T) for 1h and incubated 
with the primary antibody of interest overnight at 4°C. After incubation with HRP-
conjugated secondary antibody (Cell Signaling Technology, Beverly, MA, USA), bands 
were visualized by chemiluminescent detection ChemiDoc XRS (Bio-Rad) using 
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ECL™ Western Blotting Detection Reagents (Sigma Aldrich, GE Healthcare, 
RPN2209).  
For ERK5 detection, cells were washed with 1x PBS and lysed in ice-cold lysis 
buffer (140 mM NaCl; 10 mM EDTA; 10% glycerol; 1% Nonidet P-40; 20 mM Tris pH 
7.0;1% SDS). Immediately before use, the following proteases and phosphatases 
inhibitors have been added to extraction buffers: 1x Prothease Inhibitor (PI), β-
Glycerophosphate 2mM; PMSF 1 mM; sodium phosphate 1 mM and sodium 
orthovanadate 1 mM. After scraping the cells from the dishes, samples were incubated 
in ice for 10 minutes and then centrifuged at 14000 rpm at 4 °C for 10 min. Supernatant 
was transferred into new tubes and quantified with Coomassie Protein Assay Kit 
(Thermo Scientific, Rockford, IL, USA). For ERK5 immunoprecipitation, the lysate 
obtained with the same lysis protocol was incubated with 1µg of ERK5 C7 antibody (sc-
398015, Santa Cruz Biotechnology) and Protein A/G PLUS-Agarose (Santa Cruz, sc-
2003) beads overnight at 4°C. The immune complexes were recovered by a short 
centrifugation followed by 3 washes with 1 ml of cold lysis buffer. Samples were then 
boiled in electrophoresis sample buffer and loaded in SDS-PAGE gels. After transfer to 
nitrocellulose membranes (Bio-Rad, Hercules, CA, USA), these were blocked for 1 h in 
5% BSA in PBS-T 0.05% and then incubated overnight with the corresponding 
antibody. After washing with PBS-T 0.05%, membranes were incubated with HRP-
conjugated secondary antibodies for 1 hour, washed and bands visualized by 
chemiluminescent detection ChemiDoc XRS (Bio-Rad). For the develop, we used 
Luminata Crescendo Western HRP Substrate (Millipore) a premixed, ready-to-use 
reagent for chemiluminescent detection in western blotting applications that employ 
horseradish peroxidase (HRP)- conjugated antibodies. Images were recorded as TIFF 
files through the Quantity One software (Bio-Rad) and the quantification was performed 
using ImageJ software. The signal was measured as a corrected total cell fluorescence 
(CTCF), calculated as product between the Integrated Density, the Area of selected 
band and the Mean fluorescence of background readings. Each band is normalized on 
housekeeping and related to control. 
Antibodies used are listed above: 
 
Protein Source Notes Cat. No. Company 
p21Waf1/Cip1 rabbit 
monoclonal 
12D1 #2947 Cell Signaling Technology, 
Danvers, MA, USA 
BRAF mouse 
monoclonal 
F-7 sc-5284 Santa Cruz Biotechnology, 





 #3372 Cell Signaling Technology, 
Danvers, MA, USA 
ERK5 Mousemonocl
onal 
C-7 sc-398015 Santa Cruz Biotechnology, 





 #3371 Cell Signaling Technology, 
Danvers, MA, USA 
pERK5-S753 rabbit    Kind gift of Dr. Pandiella 





 #9101 Cell Signaling Technology, 
Danvers, MA, USA 
ERK1/2 rabbit 
polyclonal 
C-16 sc-93 Santa Cruz Biotechnology, 





 #9121 Cell Signaling Technology, 





#8516 Cell Signaling Technology, 
Danvers, MA, USA 
Actin mouse 
monoclonal 








F-8 sc-13119 Santa Cruz Biotechnology, 
Santa Cruz, CA, USA 
Fibrillarin goat 
polyclonal 
D-14 sc-11336 Santa Cruz Biotechnology, 
Santa Cruz, CA, USA 
Lamin A rabbit 
polyclonal 
H-102 sc-20680 Santa Cruz Biotechnology, 
Santa Cruz, CA, USA 




sc-56143 Santa Cruz Biotechnology, 
Santa Cruz, CA, USA 
GAPDH goat 
polyclonal 
V-18 sc-20357 Santa Cruz Biotechnology, 
Santa Cruz, CA, USA 
Cyclin D1 mouse 
monoclonal 
A-12 sc-8396 Santa Cruz Biotechnology, 
Santa Cruz, CA, USA 
CDK1 rabbit 
polyclonal  
 sc-954 Santa Cruz Biotechnology, 
Santa Cruz, CA, USA 
Cyclin B rabbit 
polyclonal  
H-433 sc-752 Santa Cruz Biotechnology, 
Santa Cruz, CA, USA 
pMBP mouse 
monoclonal 




F-6 sc-271524 Santa Cruz Biotechnology, 
Santa Cruz, CA, USA 
α Tubulin mouse 
monoclonal 
 sc-32293 Santa Cruz Biotechnology, 
Santa Cruz, CA, USA 
Table 3.2 List of antibodies used in the study. 
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3.7 Cell fractionation 
For cell fractionation, cells were harvested in Trypsin-EDTA (0,05% Trypsin, 0,53 mM 
EDTA, Invitrogen) to preserve cellular integrity and centrifuged for 5 minutes at 1500 
rpm. Pellet was lysed in the buffer A for the cytoplasmic extract (20mM Hepes buffer, 
10 mM KCl, 1 mM EDTA, 0.2% NP-40, 10% Glycerol) added with 1X Complete 
EDTA-free Protease Inhibitor Cocktail (Roche Applied Science) and phosphatase 
inhibitors. After incubation in ice of 15 minutes, the preparation was centrifuged and the 
cytoplasmic extract was collected in the resulting supernatant. The pellet (nuclei and 
membranes) was dissolved in ice-cold lysis buffer (140 mM NaCl; 10 mM EDTA; 10% 
glycerol; 1% Nonidet P-40; 20 mM Tris pH 7.0;1% SDS, 1x PI,β-Glycerophosphate 
2mM; PMSF 1 mM; sodium phosphate 1 mM and sodium orthovanadate 1 mM) and 
incubated for 10 minutes in ice. The sample was centrifuged for 10 minutes at 14000 
rpm and the nuclear protein extract collected from the supernatant. Nucleus-cytoplasm 
fractions have been quantified with Coomassie Protein Assay Kit (Thermo Scientific, 
Rockford, IL, USA) and resolved in SDS-PAGE as described above. 
In other experiments to obtain also the chromatin bound fraction, the subcellular 
fractionation was performed using the Subcellular Protein Fractionation Kit (Pierce, 
Thermo Fisher Scientific, Waltham, MA, USA). The kit includes different buffers that 
enable stepwise separation and preparation of cytoplasmic, membrane, nuclear soluble, 
chromatin-bound and cytoskeletal protein extracts from cultured cells through 
sequential centrifugations. Immediately before use, protease inhibitors have been added 
to extraction buffers to maintain extract integrity and function. The adherent cells were 
harvested with trypsin-EDTA and then centrifuged at 500 g for 5 minutes. The cell 
pellet was washed with ice-cold PBS 1X and centrifuged at 500 g for 2-3 minutes. The 
first reagent added to a cell pellet (Cytoplasmic Extraction Buffer- CEB) causes 
selective permeabilization of cell membrane and the release of soluble cytoplasmic 
contents. The second reagent (Membrane Extraction Buffer- MEB) dissolves plasma, 
mitochondria and endoplasmic reticulum/golgi membranes but does not solubilize 
nuclear membranes. After recovering the intact nuclei by centrifugation, the Nuclear 
Extraction Buffer (NEB) yields the soluble nuclear extract. Finally, a second nuclear 
extraction is performed to release the chromatin-bound nuclear proteins by adding 5 µL 
of 100 mM CaCl2 and 3 µL of Micrococcal Nuclease per 100 µL of room temperature 




3.8 ERK5 kinase assay 
Kinase activity of endogenous ERK5 was measured using a non-radioactive ERK Assay 
Kit (#17-191, Merck Millipore, Billerica, MA, USA). This in vitro kinase assay allows 
to measure the phosphotransferase activity of an immunoprecipitated MAP Kinase on a 
specific substrate (myelin basic protein, MBP). The phosphorylated substrate is then 
analyzed by immunoblot analysis, probing with a monoclonal Phospho-specific MBP 
antibody; the total MBP antibody was used as control of total MBP levels. ERK5 
protein was immunoprecipitated as described above and 500 µg of immunoprecipitated 
protein was incubated for 30 minutes at 30°C in agitation in presence of Mg2+/ATP 
cocktail, the assay dilution buffer (ADBI), the Map Kinase substrate cocktail (MBP) 
and the inhibitor cocktail. The reaction mixture was recovered by a short centrifugation. 
For SDS-PAGE and immunoblot analysis, we used 5µl of the reaction mixture 
(approximately 2µg of phosphorylated-MBP), adding 5µl of 1X PBS and 10µl of 2X 
Laemmli sample buffer. Samples were then boiled and loaded in double in SDS-PAGE 
gels. After transfer to nitrocellulose membranes (Bio-Rad, Hercules, CA, USA), these 
were blocked with 6% non-fat dry milk in PBS-T 0.05% for 1 hour at room temperature 
with constant agitation. The nitrocellulose membrane was incubated with 0.5-2µg/ml of 
anti-phospho-MBP, clone P12, and with the total MBP, clone F-6, overnight with 
agitation at 4°C. After three washes with PBS-T 0.05%, membranes were incubated 
with a goat anti-mouse HRP conjugated IgG secondary antibodies for 1 hour and 
washed. Signal was visualized by chemiluminescent detection by ChemiDoc XRS (Bio-
Rad), using Luminata Crescendo Western HRP Substrate (Millipore). 
 
3.9 Luciferase assay 
To measure the MEF2 transcriptional activity we used the luciferase reporter 3XMEF2-
luc (plasmid# 32967 was a gift from Ron Prywes, Addgene, Teddington, UK) in 
combination with Renilla luciferase pRL-TK reporter vector (Promega, Madison, WI) 
to control for transfection efficiency and to normalize luciferase activities; pcDNA 
vector was used to equal DNA amounts. Cells were co-transfected with equimolar 
amounts of wt ERK5 in combination with the empty vector pCAG, constitutively active 
MEK5 (MEK5DD) or BRAF-V600E plasmids to evaluate the modulation of the 
transcriptional activity of MEF2 promoter. To measure GLI transcriptional activity, we 
used a GLI-responsive luciferase reporter (p8x3GLI-BS, GLI-BS) which contains 8 
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direct repeats of the GLI consensus sequence GACCACCCA cloned upstream the 
luciferase gene (kind gift from H. Sasaki) (Sasaki, H. et al., 1997). The activity of the 
endogenous pathway was evaluated in NIH3T3 cells (seeded 25000 cells/well in 12 
well plate in DMEM 2.5% FBS, 1% Penicillin-streptomycin, 1% L-Glutamine). Cells 
were treated with SAG 100 nM for 48 hours and with increasing doses of XMD8-92 for 
the last 16 hours. The transcriptional activity of ectopic GLI was evaluated seeding 
M26c, SSM2c and HEK293T (85000 cells/well in 12 well plate plate in DMEM 2.5% 
FBS, 1% Penicillin-streptomycin, 1% L-Glutamine) and co-trasfetting cells with the 
reporter vector p8x3GLI-BS (GLI-BS) (Sasaki, H. et al., 1997) and low amount of GLI1 
expression construct. The effect of ERK5 inhibition on transcription was evaluated 
treating cells with increasing amount of XMD8-92 for 16 hours or cotrasfecting cells 
with two different shRNA for ERK5 silencing described above (shERK5 262, shERK5 
275). After 48 hours from transfection, cells were harvested with Passive Lysis buffer 
(Promega). Luminescence was measured using the Dual-Glo Luciferase Assay System 
(Promega) and the GloMax® 20/20 Luminometer (Promega). 
 
3.10 Xenografts 
In the first set of experiments, A375 and SSM2c melanoma cells transduced with LV-c 
or LV-shERK5 were resuspended in Matrigel (Corning, www.corning.com)/DMEM 
(1/1) and subcutaneously injected (10000 cells/injection) into lateral flanks of adult (8 
weeks) female athymic-nude mice (Foxn1 nu/nu) (Harlan Laboratories, Udine, Italy). 
Number of animals per group was 6 for A375 and SSM2c LV-shERK5 and 7 for 
SSM2c LV-c. In the second set of experiments, parental A375 cells were 
subcutaneously injected as above. Once tumors were palpable (4 mm3), mice were 
randomized in four groups of 9 mice each and treated intraperitoneally (IP) twice a day 
for 19 days with vehicle (30% 2-hydroxypropyl-β-cyclodextrin), XMD8-92 (25 
mg/Kg), Vemurafenib (20 mg/Kg) or a combination of both drugs. In both experiments 
subcutaneous tumor size was measured three times a week with a caliper. Tumor 
volumes were calculated using the formula: V=W2 x L x 0.5, where W and L are, 
respectively, tumor width and length. The experiments were approved by the Italian 
Ministry of Health (Authorization n. 213/2015-PR) and were in accordance with the 





3.11 Statistical analysis 
Data represent mean ± SEM or mean ± SD values calculated on at least 3 independent 
experiments. P-values were calculated using one-way ANOVA when more than two 
samples were analyzed or Student t-test when two samples were compared. Analysis of 
in vivo combined treatments were performed using the false discovery rate (FDR) 
adjustment for multiple comparisons. A two-tailed value of p<0.05 was considered 







4.1 ERK5 is consistently expressed and active in human melanoma 
In the last few years, the involvement of the MEK5/ERK5 pathway has been described 
in the pathogenesis of different types of cancers (Hoang et al., 2017). However, its role 
in melanoma is not well established. To assess whether alterations in components of the 
ERK5 pathway occur in melanoma samples, we have consulted the cBioPortal for 
Cancer Genomics, an open platform for interactively exploring multidimensional cancer 
genomics data sets in the context of clinical data and biologic pathways. The cBioPortal 
provides visualization, analysis and download of large-scale cancer genomics data sets 
(Cerami et al., 2012; Gao et al., 2013). In silico data analysis of primary and metastatic 
melanomas obtained from the Skin Cutaneous Melanoma data set (TCGA, Provisional) 
indicated that 47% of human melanomas presented mutations, gene copy number or 
mRNA alterations in several components of the ERK5 signaling. These alterations 
involve activators of the pathway, such as MAP3K2, MAP3K3 and MAP2K5 
(alternative name for MEK5), MAPK7 itself (the gene encoding for ERK5) and 
downstream targets of the pathway, including members of the family of MEF2 
transcription factors (Kato et al., 1997) (i.e. MEF2A, MEF2B, MEF2C and MEF2D) 
(Figure 4.1A). 
The presence of alterations in the MEK5/ERK5 pathway is relevant for 
prognosis of melanoma patients, as shown by the Kaplan-Meier curves in Figure 4.1B. 
Indeed, melanoma patients with MAPK7 alterations (including mRNA upregulation and 
MAPK7 amplifications, but not deletions) showed reduced disease free survival (p = 
0.042) and a trend toward shorter overall survival (p = 4.793e-4) compared to patients 





Figure 4.1 Genomic analysis of the ERK5 pathway and survival of melanoma patients with ERK5 
alterations. A) Genomic profiles of components of the ERK5 pathway in melanoma patients obtained 
from the Skin Cutaneous Melanoma data set (TCGA, Provisional) using cBioportal database 
(http://www.cbioportal.org). Shown are 223 out of 479 (47%) primary and metastatic melanomas with 
gene copy number and mRNA alterations. Putative passenger mutations are not included. MAPK7 is the 
gene coding for ERK5/BMK1. MAP2K5 encodes for MEK5. B) Kaplan-Meier Overall Survival (OS) and 
Disease Free Survival (DFS) in melanoma patients with (red) or without (blue) ERK5 genetic alterations 
(data set restricted to “AMP EXP >=2”, in order to exclude patients harboring MAPK7 deletion). Median 
months survival: 43.8 vs. 85 (p = 4.79e-4, log-rank test); median months disease free: 35 vs. 51.5 (p = 
0.042, log-rank test). OS and DFS curves were obtained from cBioportal database. 
 
These preliminary data prompted us to investigate the role of ERK5 in 
melanoma, starting from its expression and activation in this tumor. We analyzed the 
expression of ERK5 protein level in a panel of 8 melanoma cell lines, including 
commercial and patient-derived cell lines. Western blot analysis shows that ERK5 is 
expressed in all melanoma cell lines analyzed and in normal human epidermal 
melanocytes (NHEM) (Santini et al., 2014) (Figure 4.2). Moreover, it is important to 
note that the majority of melanoma cell lines tested (SK-Mel-5, SK-Mel-2, MeWo, 
SSM2c and M26c) presented a slower electrophoretic migration band in ERK5, 




Figure 4.2 Expression of ERK5 in human melanocytes and commercial (lane 1-6) and patient-derived 
(lanes 7 and 8) melanoma cell lines. Cells were serum starved for 24 hours and total cell lysates were 
obtained. GAPDH was used as loading control. NHEM: normal human epidermal melanocytes. Arrow 
indicates phosphorylated forms of ERK5. 
 
The existence of a phosphorylated form of ERK5 indicates that this kinase may 
be activated in our cells, but it is not enough to prove its activity. To clarify this aspect, 
we perform an in vitro kinase assay on immunoprecipitated ERK5 in four cell lines 
chosen for subsequent experiments. We used patient-derived SSM2c and M26c 
melanoma cells, that harbor wt BRAF, and A375 and SK-Mel-5 cell lines, that express a 
mutated BRAF (V600E). The in vitro kinase assay showed that ERK5 is constitutively 
active in all four cell lines, as evidenced by the phosphorylation of the myelin basic 
protein (MBP) used as substrate for the assay. The control of the experiment is 
represented by IgG, which only exhibit the total form of MBP and not the 
phosphorylated one, to demonstrate that the kinase activity highlighted in the samples is 
only due to the immunoprecipitated ERK5 (Figure 4.3A).  
ERK5 nuclear translocation is another key event for the activity of ERK5, that 
has to enter in the nucleus in order to phosphorylate target proteins (Gomez et al., 
2016). Therefore, we evaluated ERK5 intracellular localization and found that ERK5 





Figure 4.3 ERK5 is active in melanoma cells. A) In vitro kinase assay from immunoprecipitated ERK5 in 
4 melanoma cell lines. IgG is a control sample without anti-ERK5 antibody. MBP was used as loading 
control. B) Expression of ERK5 in nuclear and cytoplasmic extracts in 4 melanoma cell lines. GAPDH 
and Fibrillarin were used as cytoplasmic or nuclear markers, respectively. 
 
All together these data indicate that ERK5 is consistently expressed and active in 
human melanoma, suggesting that the ERK5 pathway might be important in this tumor. 
 
4.2 ERK5 is required for melanoma cell proliferation in vitro and xenograft growth 
In order to assess the role of ERK5 in melanoma cell proliferation, we performed 
genetic silencing of ERK5 using short hairpin RNAs and pharmacological inhibition of 
ERK5 and MEK5 with specific inhibitors. 
 
4.2.1 Genetic inhibition of ERK5 reduces melanoma cells proliferation in vitro and 
in vivo 
ERK5 has been reported to play a relevant role in the growth of several types of cancer, 
including aggressive breast and prostate cancers, hepatocellular carcinoma and multiple 
myeloma (Al-Ejeh et al., 2014; McCrackenet al., 2008; Carvajal-Vergaraet al., 2005; 
Rovida et al., 2015; Yang et al., 2011; Simões et al., 2016). To understand the 
biological role of ERK5 in melanoma, we investigated the effects of ERK5 inhibition in 
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the proliferation of melanoma cells. A375 and SSM2c cells were transduced with 
lentiviral vectors expressing shRNA against ERK5 (LV- shERK5) or a non-targeting 
shRNA (LV-c) (Rovida et al., 2015). Five days post-transduction and 3 days after 
selection with puromycin, cells were harvested, lysed and analyzed by Western blotting 
to verify the ERK5 silencing, as showed in Figure 4.4B. ERK5 silencing drastically 
reduce ERK5 protein levels, without affecting ERK1/2 amount. Using the same 
lentiviral vectors, we assessed a proliferation assay by viable cell count. ERK5 silencing 
markedly reduced the growth of melanoma cell lines harboring either wt (SSM2c) or 
mutated form (V600E) of BRAF (A375), indicating that ERK5 is essential for 
melanoma cell proliferation in vitro (Figure 4.4A). 
 
 
Figure 4.4 Genetic silencing of ERK5 drastically reduces melanoma cell growth in vitro. A) Growth 
curves of A375 and SSM2c cells transduced with LV-shERK5 or LV-c lentiviruses. Data shown are mean 
± SD. B) Western blot shows ERK5 silencing efficiency. GAPDH was used as loading control. 
 
To confirm our in vitro results, A375 and SSM2c melanoma cells stably 
transduced with LV-c or LV-shERK5 were subcutaneously injected into athymic nude 
mice and tumor growth was monitored to investigate whether ERK5 regulates 
melanoma growth in vivo. ERK5 silencing drastically reduced A375 xenograft growth 
and diminished by 70% SSM2c xenografts compared to LV-c (Figure 4.5A-D). The 
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table in Figure 4.5 shows that ERK5 silencing reduced also the tumor take, with a 
delayed tumor appearance in both cell types (Figure 4.5E), supporting the role of ERK5 
in melanoma growth. Western blot analysis of tumors dissected at the end of 
experiments, confirmed the drastic reduction of ERK5 in LV-shERK5 transduced cells 
(Figure 4.5F).  
 
 
Figure 4.5 ERK5 silencing reduces melanoma xenograft growth. A, B) In vivo tumor growth after 
subcutaneous injection of 1x104 A375 or SSM2c melanoma cells transduced with LV-c or LV-shERK5 
lentiviruses. Data shown are mean ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001. C, D) Representative 
images of A375 and SSM2c xenografts in athymic nude mice. Bar = 10 mm. E) Table shows tumor take 
(number of tumors formed per number of injections) and latency (time from injection to tumor 
measurability) for each group. Data shown are mean ± SEM. F) Western blot analysis of tumors derived 




Altogether, these results indicate that ERK5 is required for melanoma cell 
growth in vitro and in vivo, thus confirming its critical role in melanoma cell 
proliferation. 
 
4.2.2 Pharmacological inhibition of ERK5 pathway decreases melanoma cell 
growth 
To confirm the promising results obtained with the genetic inhibition of ERK5 and in 
view of a possible translation to the clinics, we performed pharmacological inhibition of 
the MEK5/ERK5 pathway using two inhibitors: XMD8-92, that compete for the ATP 
site of ERK5 reducing its auto-phosphorylation and activation (Yang et al., 2010), and 
BIX02189, an inhibitor of MEK5, the kinase upstream ERK5 (Tatake at al., 2008). 
Either drugs, as expected, efficiently reduced ERK5 activation, abolishing ERK5 
phosphorylation as shown by disappearance of the slower ERK5 migrating band in the 
SK-Mel-5 melanoma cell line. Western blot shows that either inhibitors specifically 
target ERK5, without affect ERK1/2 phosphorylation (Figure 4.6). 
 
 
Figure 4.6 Pharmacological inhibition of the MEK5-ERK5 signaling reduces ERK5 phosphorylation. 
Western blot analysis shows effects of BIX02189 (10 µM) or XMD8-92 (5µM) on ERK5 in SK-Mel-5 
melanoma cells. Both treatments abolished the slower migrating form (arrow) of phosphorylated ERK5, 
compared to vehicle treated cells (DMSO, Control). GAPDH was used as loading control.  
 
Commercial cell lines (A375, SK-Mel-5 and 501-Mel) and patient derived cell 
lines (SSM2c, M26c) were treated with increasing doses of drugs and viable cells 
(trypan blue-negative) were counted after 72 hours. Both XMD8-92 and BIX02189 
treatments decreased the number of viable cells in a dose dependent manner in several 
melanoma cell lines expressing either wt (SSM2c, M26c) or BRAF-V600E (A375, SK-
Mel-5 and 501-Mel) (Figure 4.7A, B). IC50 values, calculated using GraphPad Prism, 
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ranged between 2.3 and 3.7 µM for XMD8-92 and from 5.4 to 7.1 µM for BIX02189. 
The table in Figure 7C shows also the IC50 values for Vemurafenib, the specific 




Figure 4.7 Effect of pharmacological inhibition of ERK5 pathway in the growth of melanoma cells. A, 
B) Dose-response curves of XMD8-92 (A) and BIX02189 (B) in a number of melanoma cell lines after 
72 hours of treatment; DMSO was used as control (CTR). Data shown are mean ± SD. C) IC50 values for 
XMD8-92, BIX02189 and Vemurafenib in melanoma cells treated for 72 hours. IC50 values were 
calculated using GraphPad Prism. 
 
Recent reports suggested the possibility that the efficacy of existing ERK5 or 
MEK5 inhibitor could be due to secondary effect on BRD protein family (Lin et al., 
2016) or on TGFβ (Park et al., 2016). To exclude possible off target effects of XMD8-
92 and BIX02189, we used a recently developed and more specific ERK5 inhibitor, 
JWG-045 (Williams at al., 2016). Compared with the tested inhibitors, we observe an 
analogous activity of JWG-045 in the reduction of melanoma cells proliferation, with an 
IC50 value near to the value calculated for BIX02189. In Figure 4.8, we show the 
treatment of the A375 cell line with JWG-045, but similar results were obtained also for 





Figure 4.8 Effect of the novel ERK5 inhibitor JWG-045 on the growth of A375 melanoma cells. IC50 of 
JWG0-45 in A375 cells after 72 hours of treatment using GraphPad Prism software. 
 
Our results indicate that ERK5 pathway inhibition reduces cell growth in 
melanoma cells. To clarify the mechanism at the basis of this biological effect, we 
performed cell cycle analysis. In BRAF-V600E-expressing cells (A375 and SK-Mel-5), 
treatment with either XMD8-92 or BIX02189 markedly reduced the fraction of cells in 
S phase increasing those in G0/G1 phase. In addition, treatment with BIX02189 
significantly reduced the number of cells in G2/M phase (Figure 4.9A, B). Consistently, 
in BRAF-V600E-expressing cells BIX02189 and, to lesser extent, XMD8-92 reduced 
the level of pRb (Ser807) and, XMD8-92 in particular, increased the expression of the 
Cyclin Dependent Kinase inhibitors (CDKi) p21. Finally, the expression of Cyclins D1 





Figure 4.9 Pharmacological inhibition of MEK5-ERK5 pathway affects cell cycle distribution in 
melanoma cells harboring BRAF-V600E. A, B) Cell cycle phase distribution plots and values (tables) of 
BRAF-V600E expressing cells (A375 and SK-Mel-5). Cells were treated for 48 hours with XMD8-92 (5 
µM) or BIX02189 (10 µM). Data shown are mean ± SD. *p<0.05, **p<0.01 as determined by Student t-
test. C) Expression or phosphorylation status of cell cycle regulators in cells treated for 24 hours with 
XMD8-92 (5 µM) or BIX02189 (10 µM). Controls were treated with DMSO. Vinculin was used as 
loading control. 
 
In wt BRAF melanoma cells (SSM2c and M26c), BIX02189 slightly affected 
cell cycle distribution, with a trend toward an increase of the number of cells in S phase 
and a reduction of those in G2/M phase. On the other hand, XMD8-92 treatment 
resulted in a marked accumulation in G2/M phase at the expense of those in G0/G1 and 
S phases (Figure 4.10 A, B), with an increased expression of p21 in both SSM2c and 
M26c cells. Accordingly, with XMD8-92 or BIX02189 treatment no differences were 





Figure 4.10 Pharmacological inhibition of MEK5-ERK5 pathway affects cell cycle distribution in 
melanoma cells harboring wt BRAF. A, B) Cell cycle phase distribution plots and values (tables) of wt 
BRAF expressing cells (SSM2c and M26c). Cells were treated for 48 hours with XMD8-92 (5 µM) or 
BIX02189 (10 µM). Data shown are mean ± SD. *p<0.05, **p<0.01 as determined by Student t-test. C) 
Expression or phosphorylation status of cell cycle regulators in cells treated for 24 hours with XMD8-92 
(5 µM) or BIX02189 (10 µM). Controls were treated with DMSO. Vinculin was used as loading control. 
 
We confirmed the specific effect of XMD8-92 on ERK5 using the JWG-045, 
that shows weak binding to BRD4 (Williams et al., 2016). This new inhibitor exhibited 
an effect similar to that observed for XMD8-92 on cell cycle phase distribution, 
confirming that the effect of XMD8-92 does not appear to be due to inhibition of BRD 





Figure 4.11 The novel ERK5 inhibitor JWG-045 affects cell cycle distribution. A, B) Cell cycle phase 
distribution plots and values (tables) of wt BRAF expressing cells (SSM2c and M26c) treated for 48 
hours with JWG-045 (5 µM). Data shown are mean ± SD. *p<0.05, **p<0.01 as determined by Student t-
test. 
 
All together these results demonstrated that pharmacological inhibition of the 
MEK5-ERK5 signaling in vitro mimics the effects of ERK5 genetic silencing in the 
reduction of melanoma cell proliferation. 
 
4.3 Oncogenic BRAF increases ERK5 activity 
BRAF is mutated in about 50% of melanomas and is one of the most important target 
for melanoma therapy (Davies et al., 2002). Since our findings indicate that ERK5 is 
important for melanoma proliferation, we investigated whether BRAF modulates ERK5 
activation. To address this point, we first assessed the effect of oncogenic BRAF on 
ERK5 protein levels by overexpressing BRAF-V600E in HEK-293T and melanoma 
cells that express wt BRAF. In both cell types, BRAF-V600E significantly increased 




Figure 4.12 Oncogenic BRAF enhances levels of endogenous ERK5 protein in HEK-293T and M26c 
melanoma cells. Cells were transfected with control empty vector (pcDNA) or BRAF-V600E expressing 
plasmid and lysed after 24 hours. Western blots were performed with the indicated antibodies. 
Overexpression of BRAF-V600E is confirmed by marked phosphorylation of ERK1/2. Tubulin or Actin 
were used as loading control. Quantification of ERK5, normalized for the housekeeping, is reported in the 
graphs. Histograms represent mean ± SD from three independent experiments. *p < 0.05. 
 
To better understand the mechanism by which oncogenic BRAF affects ERK5 
protein levels, we studied the effect of its overexpression on ectopic ERK5. Oncogenic 
BRAF, either overexpressed wt or with V600E mutation, increased both ERK5 protein 
level and phosphorylation at different residues. Indeed, oncogenic BRAF induced 
robust phosphorylation of ERK5 at Ser753 and at Thr732 (Figure 4.13), two residues in 
ERK5 C-terminal region that are putative autophosphorylation sites as well as targets of 
CDK1 and/or ERK1/2 (Díaz-Rodríguezet al., 2010, Honda et al., 2015). Ectopic 
expression of constitutively active MEK5 (MEK5DD) induced robust ERK5 
phosphorylation at Thr218/Tyr220, as expected, and increased ERK5 phosphorylation 
at Thr732 (Figure 4.13). Finally, overexpression of oncogenic BRAF induced ERK5 
phosphorylation at Thr218/Tyr220, although at a much lower level than that induced by 
MEK5DD (Figure 4.13). Ectopic expression of wt BRAF elicited similar effects on the 






Figure 4.13 Oncogenic BRAF enhances level of expression and phosphorylation of exogenous ERK5. 
M26c melanoma cells and HEK293T cells were transfected with equimolar amounts of pcDNA 
(control, -) or wt ERK5 in combination with pcDNA, constitutively active MEK5 (MEK5DD), wt 
BRAF or BRAF-V600E plasmids. Cells were lysed after 48 hours and Western blot performed with the 
indicated antibodies. BRAF-V600E markedly increases ERK5 phosphorylation at Thr218/Tyr220, 
Ser753 and Thr732. HSP90 was used as a loading control.  
 
Because Ser753 can be also phosphorylated by CDK1 (Díaz-Rodríguez et al., 
2010), whereas Thr732 is phosphorylated by both CDK1 and ERK1/2 (Honda et al., 
2015), we investigated the involvement of these two kinases in BRAF-V600E-
dependent regulation of ERK5. Treatment with the ERK1/2 inhibitor SCH772984 or the 
CDK1 inhibitor RO-3306 reduced ERK5 protein level and phosphorylation at Ser753 
and Thr732. Only their combination completely abolishes BRAF-V600E-induced 
effects (Figure 4.14). Efficacy of SCH772984 on ERK1/2 and of RO-3306 on CDK1 
was witnessed, respectively, by decreased phosphorylation of ERK1/2 and increase of 
Cyclin B, as previously reported (Nithianandarajah-Jones et al., 2012). These data 
indicate that CDK1 and ERK1/2 are involved in BRAF-dependent regulation of ERK5 





Figure 4.14 Combined inhibition of CDK1 and ERK1/2 decreases ERK5 protein level and 
phosphorylation. HEK293T cells were transfected with equimolar amounts of pcDNA (control) or wt 
ERK5 in combination with pcDNA or BRAF-V600E plasmids. Cells were treated with ERK1/2 inhibitor 
SCH772984 (0.5 µM) and/or CDK1 inhibitor RO-3306 (9 µM) during the last 18 hours of transfection. 
Cells were lysed after 24 hours and Western blot performed with the indicated antibodies. HSP90 was 
used as a loading control. 
 
Having established that oncogenic BRAF enhances protein level and 
phosphorylation of ERK5, we investigated whether also ERK5 functions were affected 
by this oncogene. First, we performed in vitro kinase assay for ERK5 in M26c cells 
transfected with BRAF-V600E and a constitutively active form of MEK5 (MEK5DD), 
used as positive control. ERK5 protein was immunoprecipitated and its kinetic activity 
was measured evaluating the phosphorylation of a specific substrate (myelin basic 
protein, MBP) by immunoblot analysis of the phosphorylated form of the substrate, 
probing with a monoclonal phospho-specific MBP antibody. The increase of the pMBP 
shows that the overexpression of BRAF-V600E enhanced ERK5 kinase activity (Figure 
4.15A). Consistently, pharmacological inhibition of BRAF-V600E with Vemurafenib 
markedly reduced basal ERK5 kinase activity in A375 and SK-Mel-5 cells after 24h of 




Figure 4.15 Oncogenic BRAF increases ERK5 kinase activity. A) In vitro kinase assay for ERK5 
immunoprecipitated from M26c cells transfected with equimolar amounts of pCAG, constitutively active 
MEK5 (MEK5DD) or BRAF-V600E plasmids. MBP was used as a loading control. B) In vitro kinase 
assay for ERK5 immunoprecipitated from A375 or SK-Mel-5 cells treated with 1 µM Vemurafenib 
(Vem) or DMSO (Control) for 24 h. MBP was used as a loading control. Blots are representative images 
from at least three independent experiments. Densitometric quantification of blots is reported on the 
bottom. 
 
ERK5 has to translocate into the nucleus to exert its proliferative activity 
(Gomez et al., 2016). Therefore, we tested whether BRAF-V600E may affect also 
ERK5 cellular localization. Overexpression of BRAF-V600E increased the nuclear 
amount of total and phosphorylated ERK5 at Ser753 and Thr732 (Figure 4.16A). 
Interestingly, even thug no transcriptional activity has been described for ERK5 so far, 
oncogenic BRAF increased the amount of ERK5 in the chromatin-bound fraction 
(Figure 4.16B). To verify whether BRAF-V600E may influence the known 
transcriptional transactivator activity of ERK5, we performed a luciferase assay using a 
luciferase reporter for MEF2, a transcription factor regulated by ERK5. In the MEF2-
luciferase reporter used in this assay, the firefly luciferase gene is under the control of 
tandem repeats of the MEF2 transcriptional response element cloned upstream of a c-
Fos minimal promoter. The luciferase assay showed that BRAF-V600E  enhanced the 
ability of ERK5 to induce transcription activity of MEF2 (Figure 4.16C), demonstrating 




Figure 4.16 Oncogenic BRAF enhances ERK5 nuclear amount and functions. A) Nucleo-cytoplasmic 
fractionation in HEK293T cells transfected with equimolar amounts of wt ERK5 in combination with the 
empty vector pCAG, constitutively active MEK5 (MEK5DD) or BRAF-V600E plasmids. BRAF-V600E 
increases level and phosphorylation of nuclear ERK5. GAPDH and Lamin B1 were used as cytoplasmic 
or nuclear markers, respectively. B) Nucleoplasm and chromatin-bound fraction from HEK293T cells 
transfected with equimolar amounts empty vector pcDNA or BRAF-V600E plasmids in presence or not 
of wt ERK5. Rb and Histone H4 were used as nucleoplasm or chromatin-bound markers, respectively. A 
and B show representative blots from at least three independent experiments. C) Quantification of dual 
reporter luciferase assay in M26c melanoma cells showing that BRAF-V600E enhances the 
transcriptional transactivator activity of ERK5. Relative luciferase activity was firefly/Renilla ratios, with 
the level induced by control equated to 1. Data represent mean ± SD of three independent experiments. 




Altogether, these data indicate that oncogenic BRAF positively regulates not 
only the ERK5 protein levels, but also ERK5 activities. Since BRAF influence seems to 
be crucial for ERK5 in melanoma, the possibility to target either BRAF and ERK5 may 
be a good strategy to inhibit melanoma cell proliferation. 
 
4.4 The combination of Vemurafenib with ERK5 pathway inhibitors provides 
enhanced inhibition of melanoma cell growth compared to single treatments 
Despite our results showed that BRAF is an upstream activator of ERK5, nuclear ERK5 
amount did not decrease after a 24-hour treatment with Vemurafenib (Figure 4.17). This 
is probably due to a MEK5-dependent phosphorylation of ERK5 upon MEK1/2 
inhibition (de Jong et al., 2016), that contributes to preserve the ERK5 protein levels. 
To assess this hypothesis, we try to inhibit simultaneously MEK5 and MEK1/2 pathway 
with a combined treatment. Indeed, the ERK5 nuclear amount is reduced in A375 and 
SK-Mel-5 melanoma cells treated only with a combination of Vemurafenib and 
BIX02189 (Figure 4.17).  
Figure 4.17 Combined inhibition of MEK5 and BRAF-V600E is required to reduce the endogenous level 
of nuclear ERK5. Cytoplasmic and nuclear extracts of A375 (A) or SK-Mel-5 (B) melanoma cells 
showing the effect of Vemurafenib (1 µM), BIX02189 (10 µM) or their combination on the expression of 
endogenous ERK5. GAPDH and Lamin A were used as cytoplasmic or nuclear markers, respectively. 
Quantification of cytoplasmic and nuclear endogenous ERK5 normalized for loading control from three 
independent experiments is shown in histograms (mean ± SD). *p<0.05 as determined by Student t-test. 
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To test whether targeting both MEK5-ERK5 pathway and BRAF leads to a 
better response than single agents also in the reduction of melanoma cell proliferation, 
we used Vemurafenib in combination with XMD8-92 or BIX02189 at IC50 
concentrations. The combination of Vemurafenib with both ERK5 inhibitor displayed 




Figure 4.18 Combination of Vemurafenib and XMD8-92 shows additive effects in reducing melanoma 
cell growth. Number of viable A375 (A) and SK-Mel-5 (B) cells treated for 72 hours with DMSO 
(Control), Vemurafenib, XMD8-92 or the combination (Vem+XMD) at the indicated concentrations. 
Histograms represent mean ± SD from one representative experiment out of three performed in triplicate. 
Bliss Independence indicates additive effects in Vem+XMD vs Vem or XMD. *p<0.05, **p<0.01, 
***p<0.001 as determined by one-way ANOVA. 
 
Taken together, these data suggest that combination of Vemurafenib with ERK5 
pathway inhibitors provides enhanced effects in reducing melanoma cell growth 
compared to single treatments. 
Finally, we want to confirm the efficacy of Vemurafenib and XMD8-92 
combination also in an in vivo pre-clinical experiment. BRAF-V600E-expressing 
melanoma cells A375 were subcutaneously injected into athymic nude mice (1x104 
cells/injection). Treatments started when tumors were palpable and tumor growth was 
measured every three days and after 19 days of treatment mice were sacrificed. Single 
treatment with low doses of Vemurafenib (20 mg/Kg) (Yang et al., 2010; Paoluzzi et 
al., 2016) or XMD8-92 (25 mg/Kg) (Al-Ejeh et al., 2014) twice a day for 19 days 
produced a 50% tumor growth inhibition compared to the control group. Combination 
treatment with Vemurafenib (20 mg/Kg) and XMD8-92 (25 mg/Kg) achieved a 
significantly greater antitumor effect than either agent alone (Combo vs Vem p=0.05; 
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Combo vs. XMD8-92 p=0.005), in line with in vitro assay (Figure 4.19). Treatment 
with single agents or their combination was generally well tolerated, without significant 
weight loss or other apparent side effects.  
 
 
Figure 4.19 Pharmacological inhibition of ERK5 improves the effect of Vemurafenib in reducing 
melanoma xenograft growth. A) In vivo tumor growth of A375 melanoma cells subcutaneously injected 
(1x104). Mice were treated at tumor appearance with Vemurafenib (20 mg/Kg), XMD8-92 (25 mg/Kg) or 
the combination. After 19 days of treatment mice were sacrificed. Data shown are mean±SEM. Combined 
treatment increased the efficacy of XMD8-92 or Vemurafenib alone. Number of tumors for each group is 
indicated. *p≤0.05; **p<0.01 as determined by one-way ANOVA. B) Representative images of A375 
xenografts in athymic nude mice. Bar = 10 mm. 
 
Altogether, these results demonstrate that the combination of Vemurafenib and 
ERK5 pathway inhibitors represents a better therapeutic strategy than single treatments 
against melanoma growth in vitro and in vivo.  
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4.5 Pharmacological inhibition of ERK5 negatively regulates the transcriptional 
activity of the Hedgehog-GLI pathway in murine NIH3T3 cells 
The evidence of a fundamental role of ERK5 in the proliferation of melanoma 
cells,supported by our results, prompted us to investigate on a possible relationship 
between ERK5 and HH pathway. The Hedgehog-GLI pathway has been shown to be 
required for growth, recurrence and metastasis of melanoma xenografts in mice (Stecca 
et al., 2007; O’Reilly et al., 2013; Jalili et al., 2013). Preliminary data from our 
laboratory indicated that ERK5 silencing in M26c melanoma cell line reduces the 
mRNA level of GLI target genes, such as PTCH1, E2F1 and CyD1 and GLI1 itself, 
suggesting a possible link between the two pathways. 
We began to investigate the effect of ERK5 on the HH pathway in physiological 
conditions, using the HH competent murine NIH3T3 fibroblasts. The treatment of 
NIH3T3 cells with the synthetic SMO agonist SAG (Chen et al., 2002) allows fully 
activation of the signaling transduction through the canonical HH pathway, leading to 
the transactivation of the downstream effectors, the GLI transcription factors. We first 
tested the effect of ERK5 on the transcriptional activity of the endogenous HH pathway 
using a luciferase assay. NIH3T3 cells were transfected with the reporter p8x3GLI-BS 
(GLI-BS) vector (Sasakiet al., 1997), which contains 8 direct repeats of the GLI 
consensus sequence cloned upstream the luciferase gene. Treatment of NIH3T3 cells 
with SAG 100nM for 48 hours led to the activation of the transcriptional activity of the 
endogenous HH pathway, as indicated by the increase of the luciferase activity. The 
treatment with increasing concentrations of XMD8-92, an ERK5 inhibitor, decreased 
the transcriptional activity of the endogenous signaling in a dose-dependent manner 




Figure 4.20 Pharmacological inhibition of ERK5 decreases the transcriptional activity of the endogenous 
HH pathway. Cells were treated with 100 nM of SAG for 48 hours to activate the HH pathway and with 
increasing doses of XMD 8-92 for 16 hours. Relative Luciferase Units (R.L.U.) is calculated as the ratio 
between the firefly/renilla signal, considering the activation induced by SAG equated to 100%. Note that 
ERK5 inhibition reduced the levels of activation of the endogenous HH pathway in NIH3T3 cells in a 
dose-dependent manner. The data represent mean±SEM of at least 3 independent experiments. 
 
This result shows that inhibition of ERK5 decreases the transcriptional activity 
of the HH pathway, suggesting a positive modulation by ERK5. 
 
4.6 ERK5 pharmacological inhibition reduces GLI1 levels in murine NIH3T3 cells 
Since Gli1 is the main read-out of an active HH signaling (Lee et al., 1997), we 
evaluated the effect of ERK5 inhibition on the levels of endogenous Gli1 and Gli2 
proteins by Western Blot. NIH3T3 cells were treated for 48h with SAG (100nM), to 
activate the HH pathway, and with a single dose of XMD8-92 (5µM), which is the 
highest concentration used to inhibit the pathway, for 24 and 48 hours. Consistent with 
luciferase assay, SAG induced full activation of the HH pathway, as shown by the 
strong induction of Gli1 protein. Treatment with XMD8-92 reduced levels of Gli1 
protein compared to SAG alone at 24 hours and, even more at 48 hours. The reduction 









































































the decrease of Gli1 levels. The efficacy of XMD8-92 treatment was demonstrated by 




Figure 4.21 Pharmacological inhibition of ERK5 decreases the level of the downstream transcription 
factors Gli1 and Gli2. Western blot analysis of NIH3T3 cells treated with SAG 100nM for 48 hours and 
XMD8-92 5µM for 24 and 48 h. Note that ERK5 inhibition progressively reduces Gli1 and Gli2 protein 
levels. The efficacy of ERK5 inhibition was confirmed by the reduction of ERK5 phosphorylation. Actin 
was used as a load control. Quantification of Gli1 and Gli2 levels normalized for loading control from 
three independent experiments is shown in histograms (mean± SD). 
 
To confirm the results obtained with XMD8-92 and to exclude off target effects 
for this drug, we used the MEK5 inhibitor BIX02189. NIH3T3 cells were treated for 
48h with SAG (100nM) and the effect of a single 5µM dose of XMD8-92 for 48 hours 
was compared with BIX02189, used at 10µM for 24 or 48 hours. The inhibition of 
MEK5 confirm a robust reduction of Gli1 and Gli2 protein levels at 24 hours and, 





















































































































of ERK1/2, confirming the specific involvement of ERK5 in the modulation of Gli 




Figure 4.22 Pharmacological inhibition of MEK5 decreases the level of the downstream transcription 
factors Gli1 and Gli2. Western Blot analysis of NIH3T3 cells treated with SAG 100nM for 48 hours, 
XMD8-92 5uM for 24 and BIX02189 10uM for 24 and 48 hours. Note that inhibition of MEK5 (BIX 
02189) or ERK5 (XMD8-92) reduces Gli1 and Gli2 protein levels. The efficacy of ERK5 inhibition was 
confirmed by the reduction of ERK5 phosphorylation. Actin was used as a load control. Quantification of 
Gli1 and Gli2 levels normalized for loading control from three independent experiments is shown in 
histograms (mean± SD). 
 
All together these results confirm that ERK5 is able to positively modulate the 
transcriptional activity of HH pathway and the expression of the downstream mediators 











































which is directly regulated by the HH pathway and acts as a powerful transcriptional 
activator of HH target genes. 
 
4.7 Pharmacological and genetic inhibition of ERK5 reduces the transcriptional 
activity of exogenous GLI1 in melanoma cells 
To verify the correlation between ERK5 and GLI1, we monitored the transcriptional 
activity of ectopic GLI1 following treatment with increasing doses of XMD8-92 in 
melanoma cells. A luciferase assay was performed in a melanoma BRAF wt cell line 
(M26c), transfected with the reporter vector p8x3GLI-BS (GLI-BS) (Sasaki et al., 
1997). The reporter was activated by co-transfecting GLI-BS with low amount of GLI1 
expression construct. Twenty-four hours after transfection, cells were treated with 
increasing doses of XMD8-92 (0.5, 1, 2.5, 5µM). Pharmacological inhibition of ERK5 
reduced GLI1 transcriptional activity in a dose-dependent manner (Figure 4.23). 
 
 
Figure 4.23 Pharmacological inhibition of ERK5 decreases the transcriptional activity of exogenous 
GLI1. M26 melanoma cells were transfected with a construct for expression of GLI1 to activate the HH 
pathway and treated with increasing doses of XMD 8-92 for 16 hours. Relative luciferase units (R.L.U.) 
is calculated as the ratio between the firefly/renilla signal, considering the activation induced by GLI1 
equated to 100%. The data represent mean±SEM of at least 3 independent experiments. 
 
These data demonstrate that ERK5 positively modulates the transcriptional 

























































After evaluating the effects of the pharmacological inhibition of ERK5 on the 
transcriptional activity of GLI factors, we verify the results obtained by genetic 
inhibition of ERK5. To assess GLI1 transcriptional activity, two lentiviral vectors 
(shERK5 262 and shERK5 275) were used in luciferase assay to silence ERK5. HEK-
293T and the melanoma cell lines SSM2c and M26c were co-transfected with p8x3GLI-
BS (GLI-BS), GLI1 and with the two lentiviral vectors targeting ERK5 (shERK5 262 or 
shERK5 275). As shown in Figure 4.24, ERK5 silencing reduces approximately by 50% 
the GLI1 transcriptional activity in all tested cell lines. Among the two lentiviral 
vectors, shERK5 275 showed better ability to reduce ERK5 levels (not shown) and 
GLI1 transcriptional activity compared to shERK5 262. 
 
 
Figure 4.24 Genetic silencing of ERK5 reduces the transcriptional activity of exogenous GLI1 in 
melanoma cells. M26c and SSM2c melanoma cells and HEK-293T cells were transfected with a construct 
for expression of GLI1 to activate the HH pathway and with two different shRNA for ERK5 silencing 
(shERK5 262, shERK5 275). Relative Luceferase Units (R.L.U.) is calculated as the ratio between the 
firefly/renilla signal, considering the activation induced by GLI1equated to 100%. The data represent 
mean±SEM of at least 3 independent experiments. 
 
In conclusion, the effect of ERK5 genetic silencing on GLI1 transcriptional 
activity confirms the results obtained by drug inhibition. However, the experimental 
data obtained are still preliminary and require further studies to confirm the interplay 





























































































































































Melanoma is the most aggressive form of skin cancer, characterized by high metastatic 
potential and mortality. The Mitogen-Activated Protein Kinases (MAPK) signaling is 
the most mutated pathway in melanoma particularly at BRAF level, which presents as 
prevalent mutation the substitution on V600E residue (Davies et al., 2002; Hodis et al., 
2012). Melanoma therapies, based on target therapy and immunotherapy, have 
improved greatly survival for this disease. However, long-term benefits of targeted 
therapy are unsatisfactory due to the onset of drug resistance. Moreover, not all patients 
respond to immunotherapy (Samatar et al., 2014; Flaherty et al., 2012; Teixidó et al., 
2015). Therefore, there is an urgent need to identify novel possible targets involved in 
melanoma growth. ERK5/BMK1 is a member of the MAPK family and regulates cell 
functions critical for tumor development. Several studies reported a direct involvement 
of ERK5 in several types of cancer, including aggressive breast and prostate cancers, 
hepatocellular carcinoma and multiple myeloma (Al-Ejeh at al., 2014; McCracken et al., 
2008; Carvajal-Vergara et al., 2005; Rovida et al., 2015; Yang et al., 2011; Simões et 
al., 2016), but its role in melanoma is less investigated. A study recently demonstrated 
the involvement of ERK5 in the onset of resistance to combination therapy with BRAF 
and MEK inhibitors in melanoma cells (Song et al., 2017). 
In this study we have investigated the role of ERK5 in melanoma and its 
interplay with two oncogenic pathways: BRAF-MEK1/2-ERK1/2 and HH signaling. 
We demonstrated the requirement of the ERK5 pathway for melanoma growth. Indeed, 
genetic silencing of ERK5 or pharmacological inhibition of ERK5 signaling with two 
chemically unrelated small molecules dramatically reduce the proliferation of 
melanoma cells harboring wt or oncogenic BRAF. Importantly, a combination of the 
BRAF-V600E inhibitor Vemurafenib and ERK5 pathway inhibitors, used at doses able 
to reduce cell proliferation by half, suppresses melanoma cell proliferation and is more 
effective than single treatments in reducing growth of human melanoma harboring 
BRAF-V600E both in vitro and in vivo. Beyond this biological effects, we showed that 
oncogenic BRAF positively regulates ERK5 expression, phosphorylation and nuclear 
localization as well as its kinase and transcriptional transactivator activities. In addition, 
we demonstrated that ERK5 modulates the activity of GLI1 and GLI2, the last 
mediators of the Hedgehog signaling. 
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Our data show that ERK5 is constitutively expressed in several melanoma cell 
lines and that the presence of ERK5 genetic alterations in melanoma correlates with 
poor prognosis. Indeed, in silico data analysis indicates that 47% of melanoma patients 
have alterations in components of the ERK5 pathway, mainly consisting of increased 
mRNA or gene amplification that are likely responsible for enhanced activation of the 
pathway. Interestingly, melanoma patients with increased mRNA or amplification of 
MAPK7, the gene encoding for ERK5, have a shorter disease free survival compared to 
patients without such alterations. Five out of 479 melanoma patients harbor MAPK7 
missense mutations on two potentially phosphorylable sites, including P789S and 
A424S, which are worth being characterized in future studies to validate their effect on 
ERK5 activity. Overall, these data identify a wide subgroup of melanoma patients that 
might benefit from targeting the ERK5 pathway. This prompted us to investigate the 
role of ERK5 in melanoma cell proliferation. 
ERK5 is expressed and active in all melanoma cell lines analyzed, supporting 
the idea that this kinase is important in melanoma. We show that pharmacological 
inhibition of the ERK5 pathway with either an ERK5 (XMD8-92) or a MEK5 
(BIX02189) inhibitor leads to a strong reduction in melanoma cell growth. In BRAF-
V600E-expressing cells, MEK5 or ERK5 inhibitors slow down cell cycle progression 
with accumulation of cells in G0/G1 phase, likely due to a decreased phosphorylation of 
Rb, a key regulator of the G1 to S phase transition. Moreover, pharmacological 
inhibition of MEK5 or ERK5 reduces Cyclin D1 levels and increases p21 expression, as 
previously reported in other cell types (Perez-Madrigal et al., 2012). In melanoma cells 
expressing wt BRAF, pharmacological inhibition of ERK5 signaling reduces melanoma 
cell growth, increasing apoptosis (BIX02189) or blocking cell cycle progression 
(XMD8-92). Recently, XMD8-92 has been reported to be a dual ERK5/BRD4 inhibitor 
(Lin et al., 2016). However, our data suggest that the effect of XMD8-92 is mainly on 
ERK5, since the use of a novel ERK5 inhibitor with much lower affinity toward BRD 
proteins (JWG0-45, Williams et al., 2016) gave similar results. More importantly, 
genetic silencing of ERK5 recapitulates, in vitro and in vivo, the effects of 
pharmacological inhibition of ERK5 pathway with both XMD8-92 and JWG0-45. All 
together these data highlight the critical role of ERK5 for growth and proliferation of 
melanoma cells with either wt or V600E BRAF. 
An intriguing point emerging from our data is that the involvement of ERK5 in 
cancer cell proliferation sustained by oncogenic BRAF or RAS is context-dependent. In 
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literature, there are conflicting reports that challenge the role of ERK5 in cell 
proliferation. Indeed, we show here that ERK5 is required for BRAF-V600E-driven 
proliferation in melanoma in vitro and in vivo. In addition, it has been reported that 
hepatocellular carcinoma cells, including HepG2 that harbor mutated NRAS (Q61L), 
are sensitive to genetic and pharmacological inhibition of ERK5 in vitro and in vivo 
(Rovida et al., 2015). In contrast, colon cancer cells with KRAS or BRAF mutations do 
not appear to be addicted to ERK5 activity for proliferation at least in vitro (Lochhead 
et al., 2016). 
Another important finding of this study is the identification of a new mechanism 
of ERK5 regulation mediated by oncogenic BRAF. Our data indicate that oncogenic 
BRAF increases ERK5 protein level, phosphorylation at several residues and kinase 
activity. More importantly, BRAF-V600E enhances ERK5 nuclear localization, 
including that in the chromatin-bound fraction, and transcriptional transactivator 
activity. This is at variance with a previous report showing that BRAF-V600E does not 
enhance ERK5-driven transcriptional activity in presence of overexpressed wt MEK5 in 
HEK293T cells (Lochhead et al., 2016). As evidenced by the effect on proliferation, 
even with regard to the transcriptional transactivator activity the effect could be context 
dependent since our experiments were performed in melanoma cells. Furthermore, the 
study from Lochhead compares the oncogenic BRAF effect only with MEK5, which 
itself induces an increase of MEF2D-mediated luciferase activity, probably masking the 
effect of oncogenic BRAF. 
We investigated the mechanism of ERK5 positive modulation by BRAF 
analyzing the phosphorylation profile of ERK5. According to our model (Figure 5.1), 
oncogenic BRAF promotes ERK5 phosphorylation at three crucial sites, promoting 
ERK5 activity and nuclear translocation. First, BRAF increases phosphorylation at 
Thr732, an event that has been associated with increased ERK5 nuclear localization and 
ERK5-dependent transcription (Honda et al., 2015). Phosphorylation at this residue is 
prevented by pharmacological inhibition of ERK1/2 and CDK1, pointing to their 
possible involvement. Second, BRAF enhances ERK5 phosphorylation at Ser753, an 
additional CDK1 target residue. Pharmacological inhibition of CDK1 does not 
completely abolish phosphorylation at this site, leaving open the possibility that Ser753 
is an autophosphorylated residue, as is the case for other residues at C-terminus of 
ERK5 (Morimoto et al., 2007; Buschbeck et al., 2002). The effect of the ERK1/2 
inhibitor SCH772984 in abrogating phosphorylation at Ser753 may indicate that 
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ERK1/2 acts upstream of CDK1, which is consistent with the presence of active CDK1 
in oncogenic BRAF overexpressing cells. Finally, overexpression of BRAF induces 
ERK5 phosphorylation at Thr218/Tyr220, suggesting that MEK5 participates in BRAF-
induced ERK5 activation (Figure 5.1). Increased ERK5 phosphorylation at 
Thr218/Tyr220 by oncogenic BRAF has been showed in a previous report, although the 
authors reached different conclusions stating that oncogenic BRAF does not stimulate 
ERK5 phosphorylation (Lochhead et al., 2016). Together, these data indicate that 
oncogenic BRAF, via CDK1, ERK1/2 and/or MEK5, transduces mitogenic signals to 
the nucleus through ERK5 (Figure 5.1). 
 
 
Figure 5.1 Proposed mechanism for oncogenic BRAF-dependent ERK5 activation. Oncogenic BRAF 
may enhance ERK5 phosphorylation and activity through CDK1 by phosphorylating ERK5 at Ser753 
and/or Thr732, through a MEK1/2-ERK1/2-dependent mechanism (Thr732) or through a MEK5-
dependent mechanism (Thr218/Tyr220). Solid lines indicate direct established regulatory interactions, 
whereas broken lines illustrate putative interactions. RO-3306 and SCH772984 are, respectively, CDK1 
and ERK1/2 inhibitors, XMD8-92 and JWG-045 are ERK5 inhibitors, BIX02189 is a MEK5 inhibitor. 
 
Our data indicate that Vemurafenib inhibits only ERK5 kinase activity, but is not 
able to reduce the level of nuclear ERK5. This effect is achieved only with a combined 
inhibition of BRAF (Vemurafenib) and MEK5 (BIX02189), thus providing the rationale 
for a combined treatment. Indeed, combination of IC50 doses of XMD8-92 and 
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Vemurafenib abolished in vitro melanoma proliferation and drastically reduced 
melanoma xenograft growth. The experiments presented here suggest that the 
combination of ERK5 pathway inhibitors with Vemurafenib could be a good strategy 
for the treatment of BRAF-mutant melanoma patients. The combination therapy we 
propose could be also important to prevent the recently reported ERK5-mediated 
resistance to Vemurafenib-Trametinib treatment in melanoma (Song et al., 2017). 
Further advocating combination therapy targeting MEK1/2-ERK1/2 and ERK5 
pathway, a recent report suggested that pharmacological inhibition of ERK1/2 may 
induce ERK5 phosphorylation at MEK5 consensus sites in colon cancer cells (de Jong 
et al., 2016). 
Another interesting finding emerging from our study is the positive modulation 
of the Hedgehog pathway by ERK5. The Hedgehog pathway is required for growth and 
proliferation of melanoma cells in vitro and in vivo (Stecca B. et al., 2007; O’Reilly KE 
et al., 2013; Jalili A et al., 2013). In cancer, constitutive activation of HH signaling may 
result from canonical activation of the pathway through the binding of Hedgehog 
ligands to the Smo receptor or from direct activation of the downstream GLI 
transcription factors by oncogenic inputs (Pandolfi et al., 2015). Several studies have 
shown that oncogenes (among which RAS/RAF/MEK/ERK pathway and AKT) 
positively modulate the activity of the HH pathway. Particularly, the MEK1/2-ERK1/2 
signaling has been shown to act upstream to the HH pathway, regulating activity and 
nuclear localization of GLI transcription factors (Rovida et al., 2015). The HH pathway 
may be also upstream of MAPK, leading to ERK1 and ERK2 activation. Interestingly, 
HH activation induced by treatment with the BRAF inhibitor Vemurafenib can lead to 
the induction of PDGFRα sustaining the reactivation of the RAS-ERK1/2 pathway 
(Sabbatino et al, 2014). This modulatory loop between HH pathway and the final 
effector of MAPK has important implications for cancer therapy, especially in 
melanoma where these two signaling play a crucial role.  
In this study we identified an interplay between HH signaling and ERK5. In 
particular, we show that ERK5 is able to positively modulate the activity of Gli1 and 
Gli2, the final mediators of the Hedgehog pathway. We investigated this regulation both 
in physiological conditions, using murine fibroblasts which are highly responsive to the 
canonical activation of the HH pathway, as well as human melanoma cell lines. In both 
physiological and cancer conditions, pharmacological inhibition of ERK5 reduces the 
transcriptional activity of Gli1 in a dose dependent manner. These results were also 
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confirmed with genetic silencing of ERK5 using a lentiviral vectors encoding for a 
specific ERK5 shRNA. To further clarify this regulation, we investigated whether 
ERK5 could also affect protein level of GLI1 and GLI2. Consistent with luciferase 
assay, inhibition of ERK5 with XMD 8-92 or BIX02189 leads a to strong reduction of 
GLI1 and GLI2 protein levels, suggesting that ERK5 positively regulates transcriptional 
activity and protein level of GLI1 and GLI2. At the moment we are elucidating whether 
this regulation occurs at the transcriptional level or through post-translational 
modifications. In particular, we plan to assess whether ERK5 directly phosphorylates 
GLI1 or GLI2, or this modulation is mediated by a third factor that is phosphorylated by 
ERK5. The identification of an interplay between ERK5 and the HH pathway could 
provide new therapeutic strategies for melanoma patients and open the way for a novel 
combined therapy for metastatic melanoma. 
In conclusion, in this study we have demonstrated the requirement of ERK5 for 
melanoma cell proliferation, and its modulation by oncogenic BRAF. In addition, 
preliminary results indicate that ERK5 positively regulates the activity of the GLI1 and 
GLI2 transcription factors. Our data suggest that targeting ERK5 might be regarded as 
first-line therapeutic approach for melanoma patients with wt or oncogenic BRAF, or as 
a potential therapeutic strategy aimed at preventing resistance to BRAF-MEK1/2 
inhibitors. The interplay with the HH pathway may be a good target to block 
reactivation of a proliferative signaling and to obtain a durable response, with an 
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